Search this site

Who are the leading MedTech M&A Advisors in Europe? Executive Summary: Landscape of Leading MedTech M&A Advisors in Europe The advisory landscape for European Medical Technology (MedTech) Mergers and Acquisitions (M&A) is distinguished by a structural bifurcation across transactional size and specialised focus. The market influence is segmented into three distinct classes: Tier 1 Global Banks, which dominate based on aggregate transaction value due to their capacity to underwrite and execute multi-billion-dollar strategic acquisitions; Tier 2 Integrated Firms, which drive high deal volume and provide comprehensive advisory services essential for mid-market and private equity-backed transactions; and Tier 3 Specialist Boutiques, whose leadership is derived from deep, qualitative expertise in niche high-growth segments like Digital Health and Healthcare AI. Recent market data confirms this segmentation. While the overall MedTech sector M&A activity surged in 2024, reaching levels second only to the 2021 peak, with 305 acquisitions announced totaling $63.1 billion year-to-date, this surge reflects a dual focus: large strategic deals securing Tier 1 prominence, alongside a rise in smaller deals sustaining the transactional volume driven by Tiers 2 and 3. A critical finding is the unique position of Rothschild & Co, which serves as a bridge between these tiers, achieving the top European ranking for M&A advisory in 2023 by both deal volume and aggregate value across the broader healthcare sector. This demonstrates their strong institutional capacity to handle large, complex transactions while maintaining broad transactional coverage throughout the continent. Strategic counsel mandates that advisor selection must precisely align with the deal profile. For massive, cross-border strategic acquisitions ($1 Billion plus), Tier 1 Global Banks are essential for their global capital markets access, financing power, and high-level execution capability. Conversely, middle market and venture capital backed companies, particularly those focused on disruptive technologies, are better served by Tier 2 and Tier 3 firms. These specialists provide superior commercial diligence, specialised regulatory insight, and unparalleled access to founder-led companies in the critical mid-market and high-growth HealthTech niches, where technological specialisation is paramount to valuation. The overall market resilience suggests that major corporate acquirers view European assets as strategically vital for portfolio replenishment and digital integration, reinforcing the long-term importance of expert European M&A advisory. European MedTech M&A Market Context Deal Flow Dynamics: Surge, Selectivity and Scale The European MedTech sector has recently demonstrated significant transactional momentum. Mergers and acquisitions activity in 2024 year-to-date (YTD) totalled $63.1 Billion across 305 announced acquisitions. This level of activity is a major indicator of corporate health and strategic necessity within the industry, reaching a point second only to the high peak observed in 2021. Despite persistent global macroeconomic headwinds, the European market is characterized by a definitive "flight to quality." This phenomenon means that high-quality assets attract intensely competitive auctions and premium pricing, evidenced by increasing deal values (a 15% rise globally in deal values during H1 2025) even as the overall transaction count has seen a decline globally. This flow of capital, highly selective in nature, is directed toward high-quality, strategically necessary targets. The increasing concentration of capital in fewer, larger transactions inherently favours the Tier 1 global financial institutions capable of handling these high-value strategic mandates. Furthermore, the MedTech venture investment ecosystem reflects increasing selectivity. While the number of funding rounds decreased (691 rounds YTD 2024), the total dollar value raised surged to $19.1 Billion, surpassing the total funding value of 2023. This concentration indicates that fewer, more mature MedTech companies are successfully reaching the scale and financial maturity required to become attractive M&A targets or secure major late-stage funding, a trend that specifically benefits advisors skilled in late-stage capital raising and successful exit strategy planning. Strategic Imperatives Driving European M&A Current European MedTech M&A activity is driven by fundamental strategic imperatives centered on innovation and consolidation. 1. Digital Transformation and AI The pursuit of high-growth segments such as AI-driven HealthTech and Digital Health is a primary engine of deal activity. These technology-centric targets are commanding premium valuations in the market, with average revenue multiples potentially reaching the range of 6–8x, or even higher, compared to the general MedTech market. The market's aggressive search for advanced capabilities, such as those related to deep learning, is generating significant deal flow, as strategic buyers recognise the necessity of securing these assets to position themselves for future healthcare delivery models. This need for sophisticated valuation and positioning in complex technology environments magnifies the importance of specialised boutique advisors (Tier 3) who possess the necessary technical literacy to accurately assess and market these high-multiple, technology-enabled targets. A generalist advisor may struggle to justify the high valuations based purely on traditional financial metrics, giving the specialised firms a significant competitive advantage. 2. Private Equity Momentum and Consolidation Private Equity (PE) firms remain profoundly influential drivers of European MedTech M&A. The sector continues to attract substantial PE capital, with Ireland serving as an example, recording an almost 140% increase in PE transactions from 2023 to 2024 in its life sciences sector. Highly active and focused PE firms such as ArchiMed and Nordic Capital are key participants, actively pursuing consolidation strategies across medical devices, consumer health, and HealthTech. This PE activity is not merely transactional; it represents a value-creation lifecycle where firms acquire and consolidate smaller European MedTech companies, often guided by Tier 2 integrated firms, to construct larger, more valuable platforms ready for eventual sale to global strategic corporate buyers or secondary PE funds. Advisors excelling in PE transaction volume are therefore critical actors, effectively serving as gatekeepers to the next generation of large MedTech assets. 3. Regulatory Environment and Risk Mitigation The rigorous regulatory environment within the European Union significantly shapes M&A diligence. The sector is currently undergoing a massive transition under the stringent Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). These regulations impose complex requirements governing device safety and performance across their entire lifecycle. The regulatory certainty (or uncertainty) of a target company directly impacts its valuation and the timeline of any transaction. This complexity necessitates the engagement of financial advisors who either possess or partner with deep technical and legal expertise to navigate regulatory compliance, intellectual property (IP), and data privacy issues, which often represent the greatest risks and potential bottlenecks in complex MedTech acquisitions. Tier 1: Global Bulge Bracket Banks These institutions command the top of the league tables based on aggregate M&A transaction value, dominating the market for mega-deals and complex, public-market transactions. Their core strength lies in their ability to provide sophisticated financing solutions and unparalleled global access for the largest strategic acquisitions, typically exceeding $1 Billion. Goldman Sachs & Co. Goldman Sachs is firmly established as a global M&A powerhouse. The firm held the #1 ranking globally as a financial advisor by M&A value in 2024 and maintained a leading regional ranking in both Europe and the US. With an astounding global value of over $1.08 Trillion advised across 430 deals in 2024 YTD, its capacity for large-scale transaction execution is unmatched. The firm sustains deep engagement with the sector, demonstrating confidence in the European market by hosting specialised events such as the European MedTech-Healthcare Conference. Furthermore, its ability to close new, oversubscribed life science funds suggests robust backing from limited partners and a continued ability to facilitate capital deployment into the sector.The firm focuses on handling the largest and most complex cross-border transactions, particularly those involving public companies and requiring substantial debt financing. J.P. Morgan (JPM) J.P. Morgan maintains a consistent position among the top global financial advisors, securing Global Rank #3 by M&A value in 2024. The institution advised on transactions totalling $805.6 Billion across 405 deals in 2024 YTD. JPM is not only a major transactional player but also a key thought leader in the MedTech and Biopharma sectors, regularly publishing comprehensive reports detailing critical trends in venture funding, licensing, and M&A activity. The firm emphasises its commitment to clients through a specialised team of bankers capable of handling the "most advanced and complex M&A and capital markets transactions," confirming their focus on strategic, large-cap mandates. Although specific European MedTech deal lists are often integrated within broader life science highlights, JPM's capacity is evident through advisory roles in major European life sciences transactions, such as AstraZeneca's $1.3 Billion buyout of CinCor Pharma. Other Global Powerhouses Other Bulge Bracket banks consistently feature prominently in the European M&A ecosystem. Morgan Stanley (Global Rank #2), Citi (Global Rank #4), and Bank of America (Global Rank #5) all rank within the top five globally in terms of M&A value and maintain significant European platforms. These firms provide the essential capacity, global network, and balance sheet strength necessary for multinational MedTech corporations engaging in major strategic M&A. It is important to acknowledge that while these Tier 1 banks dominate by aggregate dollar value, the immense scope of their global operations means their explicit MedTech focus can sometimes be less granular than the dedicated sector specialists in Tiers 2 and 3. MedTech companies whose transactions do not exceed the billion-dollar threshold, or those requiring highly specialised regulatory and commercial deep dives, often look beyond Tier 1 firms for more focused expertise. The competitive edge of Tier 1 Banks lies fundamentally in their capacity for leverage, balance sheet support and unparalleled global capital access, rather than niche, regulatory-heavy, mid-market commercial expertise. Table 1: Select Top-Ranked Global Financial Advisors by Overall EMEA M&A Value (YTD 2024) Rank (EMEA) Global Rank (Value) Company Name Global Value (USDm) Deal Count Primary European M&A Role 1 1 Goldman Sachs & Co. 1,084,689 430 Mega-deals, Financing, Public Markets Access 2 3 J.P. Morgan 805,592 405 Large Strategic Acquisitions, Capital Markets 3 2 Morgan Stanley 856,780 366 Large-Cap M&A, Private Equity Transactions 5 4 Citi 543,557 216 Cross-Border Mandates, Corporate Strategy Tier 2: Integrated Advisory and Mid-Market Powerhouses The Tier 2 category consists of highly integrated advisory firms and specialised investment banks that drive a significant portion of the European M&A market's volume. Their strength is derived from deep regional networks, comprehensive service offerings, and consistent presence in private equity-driven transactions and complex commercial diligence mandates. Rothschild & Co. Rothschild & Co. stands out as a preeminent European advisor, having achieved the distinction of being the top-ranked firm in Europe for M&A advisory in 2023 by both deal volume and value. This dual leadership status is a strong indicator of their ability to secure mandates for both large, high-value strategic transactions and a substantial volume of mid-market deals. The firm possesses a leading and established presence in handling large and complex healthcare transactions across the continent. Their long-standing European heritage and extensive regional network provide a critical advantage in winning mandates from European corporate entities, major private equity houses, and sophisticated family-owned MedTech businesses. The Big Four and Integrated Specialists Deloitte Deloitte is widely recognised as a leading mid-market M&A advisor within the life sciences and healthcare sectors in Europe. The firm’s strength is rooted in its capacity to provide integrated strategic, financial, and commercial advisory services for HealthTech and MedTech deals. This holistic approach, combining transaction execution with deep due diligence expertise across tax and operations, is highly valued by both strategic buyers and private equity investors navigating the complexities of the European regulatory landscape. Houlihan Lokey Houlihan Lokey is a consistently prominent advisor known for its dedicated healthcare group serving European clients. The firm is frequently involved in complex healthcare M&A and capital-raising assignments, maintaining high visibility in private equity-backed deals across the region. Integrated Consulting Firms (EY and KPMG) Ernst & Young (EY) and KPMG are integral to the European life sciences and healthcare deal ecosystem. While often involved in M&A execution (KPMG is explicitly mentioned as a highly regarded advisor in the broader sector), their roles often emphasise strategic consulting, operational performance optimisation, and rigorous due diligence necessary before an M&A event. They assist MedTech companies in aligning resource allocation with key performance indicators (KPIs) to maximise profit margins and ensure long-term sustainability, making them essential partners in the pre-deal phase. Regional Volume Leaders in Medical Devices Analysis of deal volume in the European medical devices sector reveals a highly active and localized mid-market environment. Data for the first nine months of 2024 indicates that Cavendish Financial was a top-ranked advisor by volume for general European medical devices M&A deals. Critically, the private equity segment of the medical devices market is intensely competitive. For the first nine months of 2024, multiple firms, Aritma, Clearwater, Deloitte NSE, Ernst & Young Global, and Houlihan Lokey, all shared the top rank in European medical devices Private Equity deal volume. This phenomenon, where multiple firms share the highest volume rank, underscores the highly fragmented and competitive nature of the mid-market advisory space. It suggests high transaction volume across many deals, but with low average deal counts per firm, which is characteristic of regional M&A. Clients in this segment prioritise deep-rooted regional connections, nuanced market access, and robust integrated diligence capacity, favoring the specific expertise of the Big Four and specialised integrated firms over the global capital capacity of Tier 1 Bulge Brackets. These firms are essential for executing the high volume of PE-backed transactions that drive market consolidation. Top-Ranked Financial Advisors in European Medical Devices M&A by Deal Volume Advisor Type Primary Role Q1 2024 Rank (Volume) Q1 2023 Rank (Volume) Focus (PE vs. General M&A) Rothschild & Co Integrated/Global Complex Transactions N/A (Top overall 2023) N/A (Top overall 2023) Large/Complex Healthcare Cavendish Financial Regional/Specialist General M&A Deals 1 1 Medical Devices M&A Clearwater Mid-Market Advisory Private Equity Execution 1 1 Medical Devices PE Deals Deloitte NSE Integrated Advisory PE, Commercial Due Diligence 1 1 Medical Devices PE Deals Houlihan Lokey Mid-Market Specialist PE, Capital Raising 1 1 Medical Devices PE Deals Aritma Mid-Market Advisory Private Equity Execution 1 - Medical Devices PE Deals Specialised MedTech and HealthTech Boutiques with Niche Expertise Tier 3 advisors focus intensively on specific segments, such as Digital Health, Health IT, and AI. Their "leading" status is measured qualitatively by their deep domain knowledge, ability to successfully position highly innovative companies, and their strong thought leadership within their dedicated niche, rather than by overall M&A value or volume across all sectors. HealthTech and Digital Health Specialists Nelson Advisors Nelson Advisors is highly recognised for its exclusive dedication to the European healthcare technology (HealthTech) sector, specifically digital health, health IT, consumer healthtech, healthcare cybersecurity, and Healthcare AI companies. The firm distinguishes itself by leveraging the entrepreneurial expertise of its founders to deliver tailored M&A, investment, and partnership guidance. Strategically, the firm focuses on guiding early-stage, high-growth companies through M&A exits, a crucial service in periods defined by tight venture capital funding and a less active initial public offering (IPO) market. While physically headquartered in London, UK, their service reach spans the UK, Europe, and North America, supporting complex, cross-border transactions. For targets focused on disruptive technology like AI, the credibility of this specialised counsel, demonstrated by sector-specific market analyses and thought leadership, often provides more value than raw global league table ranking alone. https://nelsonadvisors.co.uk ConAlliance ConAlliance is positioned as a premier M&A advisory firm focused exclusively on the global healthcare and life sciences industry. As one of the most sought-after specialist M&A advisors in Europe, ConAlliance offers bespoke, holistic support tailored to the complex needs of the industry. The firm explicitly focuses its renowned M&A advisory services on advising companies in the mid-market segment of healthcare and life sciences, boasting experience advising on more than 250 M&A transactions.25 Headquartered in Germany and the UK, their international network facilitates access to key decision-makers and healthcare-focused equity investors globally. Dedicated Healthcare Investment Banks The European market’s growing maturity and strategic importance have attracted greater specialization from US-based investment banks. Leerink Partners Leerink Partners is branded as "The Healthcare Investment Bank," with an exclusive focus on the sector, including dedicated coverage for MedTech, Tools, and Diagnostics. In a significant move highlighting the commercial opportunity in Europe, Leerink recently launched a London office to mark its international expansion. This expansion confirms that the European MedTech market has reached a critical size and maturity to warrant dedicated, sector-exclusive capital markets and M&A attention. Leerink’s deep connectivity to US capital markets and strategic buyers provides superior value, facilitating the complex, cross-border M&A that is increasingly common. Stifel Stifel’s Healthcare Investment Banking Group offers integrated solutions covering M&A, capital raising, and restructuring for organisations across the healthcare industry. Like Leerink, Stifel represents the growing trend of focused investment banks providing specialised financial advisory services to the European MedTech ecosystem. Comparative Profile of Key Specialised European MedTech/HealthTech Advisory Firms Advisory Firm Primary Focus Typical Deal Size Focus European Presence Competitive Advantage Nelson Advisors HealthTech, Digital Health, AI Mid-market, Early-Stage Exits UK, Europe, North America (London HQ) Deep HealthTech Specialisation, Founder-Led Exits ConAlliance Healthcare, Life Sciences Mid-Market Segment Germany, UK, Global Network Exclusivity in Healthcare, Bespoke M&A Advisory Deloitte Life Sciences / Healthcare Mid-Market M&A Pan-European NSE Network Integrated Strategy, Financial, and Commercial Due Diligence Leerink Partners Healthcare Investment Bank MedTech, Biopharma, Tools International Expansion (London Office) Deep US/Global Capital Markets Connectivity Strategic Advisor Selection: Mapping Expertise to Transaction Profile Selecting the optimal M&A advisor in the European MedTech sector requires a nuanced assessment of the firm's core competencies against the specific needs and risks of the transaction. The leading advisor is not always the one at the top of the generalist league tables but the one best equipped for the deal's size, sector, and geographical complexity. Key Criteria for Advisor Selection Deal Size and Capital Requirements For mega-deals, especially those involving multi-billion dollar valuations or public-to-private transactions—Tier 1 Global Banks are necessary due to their capability to organise complex financing and manage cross-border execution risk on a global scale. For the robust European mid-market ($50M–$500M), Tier 2 integrated firms offer the necessary blend of financial execution experience and local market access, often providing stronger value by reducing execution risk through comprehensive due diligence. Buyer Profile and Geographic Access The European market is highly attractive to US strategic acquirers, including major players like Stryker, Boston Scientific, and Enovis, who are actively executing deals on the continent to bolster their orthopedic, interventional, and digital portfolios. This high volume of US-inbound M&A confirms the demand for advisors who can effectively bridge the cultural, valuation, and regulatory gaps between US acquirers and European targets. Firms with established transatlantic capabilities, such as Leerink Partners and Nelson Advisors, offer superior value in facilitating these crucial cross-border mandates. Conversely, transactions involving European Private Equity firms (e.g., ArchiMed, Nordic Capital) often rely heavily on Tier 2 integrated and regional firms for access and deep-seated local relationships. Sector and Technical Nuance In high-growth segments like Digital Health and AI, the primary value driver is technology, often protected by intellectual property (IP) and tied to complex regulatory pathways. Here, specialised boutiques (Tier 3) are leading advisors, as they possess the technical literacy to accurately value complex, intangible assets and effectively position the company to a highly technical audience of buyers. When the MedTech asset is focused on disruptive technology, the advisor’s credibility, demonstrated by deep sector insight and specialized knowledge, outweighs raw global capital access. Case Study Analysis: Strategic European Acquisitions The acquisition strategies of global MedTech leaders illustrate the reliance on advisors with strong European execution capacity. For instance, Stryker's acquisition of the France-based joint replacement company SERF SAS from Menix in March 2024 was a strategic move to strengthen its orthopaedic portfolio across Europe.Although the financial advisor for this mid-sized bolt-on acquisition was not explicitly named in the public release, the seller (Menix) engaged specialised legal counsel, Paul Hastings. This choice of specialised legal support strongly suggests that the associated financial advisor in this transaction likely possessed significant regional European depth (Tier 2 or 3 capacity) rather than relying solely on a large generalist bank. The ability of major US MedTech players to successfully complete these strategic acquisitions confirms that European innovation is highly valued and that leading advisors must provide both financial expertise and seamless regional execution capabilities. Conclusions The identification of leading MedTech M&A advisors in Europe necessitates a categorical approach based on the specific transactional requirement. Mega Deals and Global Capital: For high value, strategic transactions ($1 Billion plus) requiring global capital markets connectivity and complex financing, the leading advisors are definitively the Tier 1 Global Bulge Brackets (Goldman Sachs, J.P. Morgan, Morgan Stanley). Their capacity to underwrite and manage cross-border risk on a massive scale remains unrivalled. Breadth and Integrated Mid-Market Execution: Tier 2 Integrated Advisory Firms (Rothschild & Co, Deloitte, Houlihan Lokey) are the volume leaders and the preferred partners for Private Equity transactions and mid-market deals. Rothschild & Co's recent dual leadership in value and volume marks them as a uniquely powerful, pan-European institution. These firms excel by offering integrated services, combining financial execution with essential commercial and operational due diligence required for complex European assets. Specialisation in High-Growth Sub-Sectors: For transactions involving disruptive or early-stage MedTech and HealthTech companies (especially those focused on AI, Digital Health, and Cybersecurity), Tier 3 Specialist Boutiques (Nelson Advisors, ConAlliance, Leerink Partners) are the leading advisors. Their leadership is qualitative, rooted in deep sector specialisation and the ability to command premium valuations for technology-driven assets by expertly positioning IP and regulatory compliance readiness. A critical strategic recommendation for stakeholders is to recognise that in European MedTech M&A, regulatory risk often supersedes purely financial risk. Therefore, the leading financial advisor must demonstrate a robust capacity to integrate seamlessly with top legal counsel specializing in EU MDR/IVDR compliance, data protection, and IP law (e.g., White & Case, Latham & Watkins). The ideal advisory team is a composite structure, combining the financial scale of Tier 1/2 players with the technical and regulatory precision offered by specialised boutiques and legal experts. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Hardware, Software, Apps, Devices, AI : HealthTech driving Behaviour Change to improve Patient Outcomes Executive Summary and Strategic Imperatives Defining the Digital Therapeutic Paradigm: From Connectivity to Continuous Care The digital transformation of healthcare represents a profound industry evolution, shifting the focus from episodic treatment to continuous, proactive intervention. This new paradigm, known broadly as Digital Health, utilises technology to facilitate active therapeutic engagement and deliver care outside traditional clinical settings, effectively realising the concept of "virtual hospital wards" and enabling remote diagnostics. This movement is supported by a massive and rapidly expanding ecosystem, currently comprising over 337,000 mobile health applications globally. Crucially, a growing segment of these applications focuses intensely on disease-specific management and chronic conditions, moving beyond general wellness tracking to deliver tangible clinical utility. The market has identified key areas ripe for disruption through digital integration. Data-driven companies are increasingly leading innovation in historically underserved sectors, such as women's health, offering integrated, end-to-end care pathways that personalise treatment based on continuous data streams. Similarly, the increasing professional acknowledgement of mental health’s importance has driven the emergence of more specialised mental health and well-being solutions utilising digital tools for improved accessibility and efficacy. Strategic Imperatives for MedTech Transformation The successful deployment and maintenance of sophisticated, connected medical devices necessitate a comprehensive transformation for medtech companies. The traditional model, centred on one-time device sales, is becoming obsolete in a connected world where ongoing service delivery is not merely expected but is required for sustained clinical function and regulatory adherence. This transformation requires a fundamental shift toward service-oriented business models that prioritise long-term value creation over immediate returns from device sales. Companies must invest in the foundational capabilities and infrastructure required to deliver continuous services throughout a device's operational life, including device maintenance, security monitoring, data management, and the crucial ability to provide over-the-air (OTA) software and firmware updates. Payer recognition and the acceleration of approval and reimbursement for digital tools are directly predicated on the demonstration of clinical utility and verifiable cost savings. Because Software as a Medical Device (SaMD) and Digital Therapeutics (DTx) rely on continuous software refinement, for security patches, bug fixes,and algorithmic improvements, the traditional device-only model is incompatible with the criteria required for continuous market access and reimbursement justification. Therefore, the transition to a service-oriented model is not an elective business change, but a strategic and commercial prerequisite to ensure continuous operational compliance and the necessary sustained behavioural intervention efficacy. Technological Pillars of Behavioural Intervention Connected Devices and Wearable Architecture: The Foundation of Continuous Data Capture (Hardware) The physical layer of digital health is built upon Sensor-based Digital Health Technology (sDHT). These devices, ranging from advanced wearables to smart inhalers and sophisticated glucose monitors, form the foundation for behaviour change interventions by providing a constant stream of real-time feedback and actionable data. This continuous monitoring empowers patients to effectively manage complex conditions such as asthma and diabetes. The US. Food and Drug Administration (FDA) maintains a registry of authorised sDHT medical devices, providing crucial insights into the current regulatory landscape and setting clear safety and effectiveness expectations for innovators. Remote Patient Monitoring (RPM) tools are a core component of this infrastructure. These systems utilise sensors to track critical physiologic and behavioural data, augmented by the collection of electronic Patient Reported Outcomes (ePROs) delivered via mobile applications. This data flow is essential not only for chronic condition management but also for aiding in population risk management and enabling highly personalised care delivery through continuous feedback loops. For example, Biofourmis provides FDA-approved digital therapeutics solutions for chronic heart conditions, leveraging wearable devices and its sophisticated, personalised AI platform, Biovitals. The fundamental value proposition of the hardware transitions from simple monitoring to providing the essential feedstock for algorithmic intervention. While RPM traditionally focuses on clinical metrics (eg. blood pressure, blood glucose), the key mechanism for behaviour change intervention (BCI) relies heavily on the sensor-based tracking of behavioural data, such as steps, sleep quality, and active minutes. This rich, continuous stream of data, often collected implicitly, becomes the necessary input for the personalisation engines (AI/ML) that generate targeted nudges and feedback. Software as a Medical Device (SaMD) and Digital Therapeutics (DTx) The software layer defines the intervention itself. AI/ML-based software intended to treat, diagnose, cure, mitigate, or prevent disease is classified under the FD&C Act as Software as a Medical Device (SaMD). This classification subjects the software to stringent regulatory oversight consistent with traditional medical devices. The market for Digital Therapeutics (DTx), defined by these regulated software solutions, is demonstrating robust financial growth. The DTx market was valued at approximately $4.68 Billion in 2024 and is projected to continue growing at a Compound Annual Growth Rate (CAGR) of 16.61%. This expansion reflects successful clinical adoption; out of over 360 commercially available software-based digital therapies, 140 prescription DTx are approved for patient use at home. Furthermore, the technological pillars are advancing rapidly from monitoring capabilities to diagnostic capabilities. Over 103 digital diagnostics, frequently enabled by Artificial Intelligence (AI) and Machine Learning (ML), are now commercially available. These tools go beyond tracking the response to treatment; they are used for risk assessment, accelerating diagnosis, and providing prognostic value, thereby influencing patient behaviour earlier in the care pathway through tools like risk screening and diagnosis support. The Role of the Application Layer: Designing User Interfaces as Behaviour Change Conduits The mobile application serves as the primary conduit for the patient experience, delivering personalised care instructions and Behaviour Change Techniques (BCTs). The design of this layer is critical, as connected medical devices must operate seamlessly in real-world environments and serve a diverse user set, many of whom are not healthcare professionals. Effective application design must embed core principles of usability and user-centricity. The application must simplify complex interactions and present continuous data in an accessible manner. The quality of the user interface directly impacts the ability of the SaMD to facilitate behavior change, as a poorly designed app can introduce friction that undermines motivation and adherence. Applied Behavioral Science and Engagement Design Foundational Models for Behaviour Change Interventions (BCIs) The efficacy of digital health solutions hinges on the meticulous application of established psychological and behavioral science frameworks. Building digital tools around these models maximises patient engagement and the probability of sustained behavioural conversion. The Fogg Behavior Model (FBM) provides a practical explanation of how behaviors occur in the context of digital health solutions. It posits that a behaviour (B) happens only when an individual possesses sufficient Motivation (M), high Ability (A), and a timely Trigger (T). Digital health applications leverage the FBM by simplifying tasks and interfaces (increasing Ability) and delivering personalised, context-aware prompts (Triggers) at optimal times to encourage action. The Transtheoretical Model (TTM) offers a framework for staging interventions based on a user's readiness for change. TTM recognises distinct stages: Pre contemplation (no intention of change), Contemplation (recognising the need for change),Preparation (planning action), and Action (new behaviour initiated). Designing interventions informed by TTM ensures that personalised content and challenges align with the user’s current stage, thereby maximising the relevance of the nudge and increasing the probability of conversion to sustained action. Practical Behaviour Change Techniques (BCTs) Systematic reviews of Digital Behaviour Change Interventions (DBCIs) for physical activity confirm that successful techniques revolve around three core methods: self-monitoring of behaviour, goal setting and the provision of prompts and cues. Habit formation within these systems is systematically encouraged through positive reinforcement and cues, often using automatic monitoring, descriptive feedback, self-set goals and virtual rewards. Mechanisms of Sustained Engagement: Gamification and Adherence Gamification is a powerful tool for transforming necessary, but often monotonous, health routines into intrinsically motivating experiences. By integrating game mechanics such as rewards, level progression, and challenges, patients are encouraged to consistently complete tasks and monitor their progress toward health goals. The clinical impact of this approach is measurable. Research indicates that gamified health applications improved medication adherence by 30% when compared to non-gamified counterparts, leading patients to be more consistent with medication schedules and developing a deeper understanding of their condition. Behaviour change interventions for chronic disease management frequently face challenges related to delayed feedback; for instance, it takes months to observe a change in HbA1c or long-term blood pressure reduction. Gamification provides an immediate emotional reward loop through virtual rewards and points systems, serving as a critical 'fast feedback' mechanism that maintains motivation and adherence in the absence of rapid clinical feedback. This mechanism accelerates habit formation, reinforcing desired actions in the short term to sustain engagement toward long-term clinical goals. Despite these advances, a recognised gap exists in design strategy: the lack of research and focus on implicit interaction. While many existing studies rely on explicit user effort (eg., manually logging data), high adherence is only sustainable when the intervention requires minimal conscious effort (maximising Fogg Ability). Overcoming this scalability bottleneck requires leveraging advanced AI and ubiquitous sensors to infer user context and deliver behavioural interventions ambiently, thereby solving the challenge of long-standing adherence noted in early clinical evaluations. Operationalising Behaviour Change Models in Digital Health Design Behavioural Model Core Principle Mechanism/Technique Used in Apps Design Goal Fogg Behaviour Model (FBM) Behaviour = Motivation Ability Trigger Contextual, timely prompts/cues (Triggers); simplified task flows (Ability) Maximising action completion by reducing friction and providing instantaneous cues. Transtheoretical Model (TTM) Stages of Readiness (Pre contemplation to Action) Personalised content delivery and staggered challenges based on current readiness stage Increasing the probability of conversion to the sustained action stage. Operant Conditioning / Gamification Positive Reinforcement, Rewards Virtual rewards, points systems, level progression, badges Improving adherence rates and creating short-term motivation loops to sustain long-term habit formation. Social Learning Theory (MINDSPACE) Social Influence and Modelling Community forums, peer comparisons, shared progress (Implicitly suggested by the data) Building social motivation and reinforcing positive behavioural norms. Advanced AI and Algorithmic Nudging Systems Personalised Interventions at Scale: The Necessity of AI Scaling behaviour change interventions to large populations requires sophistication far beyond static application logic. AI and Machine Learning provide the necessary complexity to move from broad intervention strategies to hyper-personalised, context-aware digital nudging. AI not only optimises behavioural triggers but also enables complex diagnostic functions within the SaMD framework, including risk screening, diagnosis support, and prognostic analysis. Deep Dive: Knowledge Graph Neural Networks (KGNN) in Health Nudging The application of advanced AI architecture is exemplified by production level systems like NudgeRank. This algorithmic nudging system utilises a novel combination of Graph Neural Networks (GNN) augmented with an extensible Knowledge Graph (KG) to deliver personalised, context-aware nudges to over 1.1 Million care recipients daily. This represents one of the largest enterprise deployments of AI dedicated to health behaviour change. The core of the architecture lies in the NudgeRank Knowledge Graph Constructor, which dynamically forms a heterogeneous graph where users and nudges are represented as nodes. Directed edges capture the historical history of user-item interactions (eg. ratings, opens). User knowledge is captured through over 130 binary markers detailing attributes and behaviours (eg., "age: 30s," "steps: 2.5k"). Nudge knowledge is also encoded, detailing the specific target segments and desired behavioural outcomes. This structure enables personalisation by mitigating the cold-start problem, allowing the system to recommend new nudges to relevant target segments based on the graph connections and shared behavioural data with similar users. A critical technical feature of the KGNN is the Diversity Mechanism. Controlled by a configurable parameter pdiversity​, this mechanism manages the proportion of nudges that are randomly sampled from the user's candidate list. This forced algorithmic exploration strategy is essential for maximising long-term learning utility by continually gathering new user-nudge interaction data, broadening user preference knowledge and preventing the model from becoming stagnant or clinically rigid over time. The system's objective is to manage the tension between maximising immediate prediction accuracy (exploitation) and gathering new data to handle changing contexts (exploration). To protect user experience and maintain long-term adherence, the Constraints Filter enforces critical business rules. This includes the Negative Rating Filter, which removes all nudges a user has actively disliked for a specified period and the Nudge Budget Filter, which limits the number of daily nudges to a configurable parameter kdaily​ to actively mitigate "nudge fatigue". By optimising the trigger timing based on real-time data and KG connections, the AI ensures the intervention occurs at the precise moment of maximum receptivity, transforming a generic manual cue into an effective, context-aware trigger. NudgeRank™ AI Architecture: Key Components and Behavioural Function Component Technical Description Behavioral Function/Value Knowledge Graph Neural Network (KGNN) Heterogeneous graph with User/Nudge nodes and interaction edges. Enables hyper-personalisation by connecting users to relevant nudges based on similar users’ behaviour; optimises the timing and context of the Trigger. Diversity Mechanism (pdiversity​) Configurable parameter for forced random sampling of candidate nudges. Ensures algorithmic exploration, broadens learning of user preferences, and prevents stagnation in recommendation patterns, crucial for long-term adaptation. Constraints Filter Enforces Negative Rating Filter and Nudge Budget Filter (kdaily​). Mitigates "nudge fatigue" and respects user feedback, safeguarding the user experience and long-term acceptance. Distributed Infrastructure Runs on Kubernetes with parallel batch scoring pipelines. Ensures performance and resilience, allowing the system to scale personalisation to over 1.1 million users without contextual latency. Quantifiable Impact of Personalised AI Rigorous evaluation of the NudgeRank system, deployed in collaboration with the Health Promotion Board of Singapore, demonstrated statistically significant efficacy at improving physical activity across the population. Key behavioural improvements included a 6.17% increase in daily steps and a 7.61% increase in exercise minutes. Furthermore, the system achieved a substantial increase in user engagement, evidenced by a 13.1% open rate, compared to a baseline system's 4%. This increase in open rate signals the clinical advantage of context-aware, hyper-personalised delivery. Clinical Validation and Outcome Evidence Chronic Disease Management Case Studies Empirical evidence confirms the transformative potential of integrated digital solutions across major chronic disease categories, demonstrating a clear causal pathway from technology-driven behaviour change to improved patient outcomes. For patients with Diabetes Mellitus, the use of real-time Continuous Glucose Monitoring (CGM) has been associated with dramatic clinical improvements. One study revealed that the proportion of patients with intensively managed diabetes who achieved an HbA1c level of <7% nearly doubled, rising from 24.6% in pre study samples to 50.8% after at least 12 weeks of CGM usage. Participants with higher baseline HbA1c levels experienced even larger absolute reductions, exceeding 1%. In Hypertension management, digital health interventions incorporating remote monitoring have achieved impressive results, doubling the success rates for blood pressure control. This improvement was particularly significant among historically underserved patient populations, demonstrating the capacity of digital delivery to overcome traditional structural barriers to care and promote health equity. Digital solutions are also effective in Weight Management. Mobile applications providing evidence-based weight loss programs have been shown to be a cost-effective and accessible alternative to intensive in-person programs. Pooled results from meta-analyses show that app usage led to a mean weight reduction of 0.84 kg, with significant decreases in BMI (median 1.8 kg/m) and waist circumference (median −3.8cm). In one study, groups receiving the intervention lost 2.6% of their body weight within the first three months. Expanding Clinical Utility: Mental Health and Integrated Pathways Beyond traditional chronic physical diseases, specialised mental health and well-being solutions continue to gain prominence. Companies in this space, such as Lyra Health and Headspace, leverage digital tools to provide scalable access to care. Furthermore, data driven approaches are increasingly used to develop integrated, end-to-end care pathways, particularly in complex fields like women’s health. Challenges in Clinical Evaluation and Frameworks Despite demonstrable positive clinical outcomes, rigorous clinical review identifies key deficiencies in evaluation methodology. Few studies adequately address the usability of these technological interventions, and the explicit reason for not utilising or citing specific behaviour theories often remains unclear. This presents a structural risk: while clinical outcomes (HbA1c, BP) are improving, the process validation for sustained engagement is weak. A critical need exists for a common assessment framework that employs a broad range of measurements.This framework should focus not just on immediate clinical metrics, but on process measurements related to motivation for health behaviour change, long-standing adherence, expenditure and patient satisfaction. The focus on immediate efficacy rather than sustained maintenance leaves a high-risk gap in understanding long-term patient retention and future development reproducibility. Clinical Efficacy of Digital Interventions: Summary of Key Outcomes Condition Technology Intervention Key Outcome Measure Observed Improvement / Change Type 1/2 Diabetes Real-Time Continuous Glucose Monitoring (CGM) HbA1c Levels 50.8% of patients achieved HbA1c <7%; >1% absolute reduction for many. Hypertension Remote Patient Monitoring (RPM) + Intervention Blood Pressure Control Success Doubled success rates in underserved patients via remote monitoring. Physical Activity AI Nudging System (KGNN-RecSys) Daily Steps & Exercise Minutes (MVPA) 6.17% increase in daily steps; 7.61%increase in exercise minutes. Overweight/Obesity Mobile Apps (Evidence-Based) Weight/BMI Reduction Pooled results showed 0.84 kg reduction; 2.6% body weight reduction in 3 months. Regulatory, Reimbursement and Ethical Frameworks Navigating the Regulatory Landscape: FDA Frameworks The oversight of digital health solutions, particularly those employing AI/ML, must contend with the rapid iteration cycles of software development. AI/ML-based software intended to treat or diagnose is classified as SaMD and is subject to the FDA’s risk categorization framework. Acknowledging that software can rapidly respond to glitches, adverse events, and safety concerns, the FDA has proposed adaptive regulatory processes, such as the Pre-Cert program. These proposals recognise that the speed of software iteration has surpassed the capacity of traditional, static regulatory pathways. This gap in oversight creates a high commercial risk for developers of continuously learning SaMD, necessitating strategic investment in regulatory compliance focused on adaptive pathways to ensure safety and effectiveness standards are maintained. Market Access and Reimbursement Market access is accelerating as payers increasingly recognise the clinical utility and documented cost savings provided by DTx solutions. This acceleration is inextricably linked to the commercial shift away from device-only sales toward the service-oriented model. Securing consistent, ongoing reimbursement streams necessitates that developers satisfy payer requirements for long-term maintenance, cybersecurity, and, most critically provide proven, durable patient outcomes over the full lifecycle of the intervention. Ethical Governance of AI-Driven Behaviour Change The deployment of sophisticated AI in health promotion introduces critical ethical considerations spanning issues of fairness, bias, and patient autonomy. AI tools carry the inherent risk of causing unintended harm through biased algorithms. If training data is unrepresentative, or if algorithms prioritise certain outcomes, this can promote discrimination or inaccurate decision-making, potentially leading to systematic errors that exacerbate existing health inequality. Algorithmic fairness is therefore not merely an ethical requirement, but a technical one for achieving efficacy at population scale. When an AI system fails for a demographic due to bias, resulting in ineffective nudges, it fundamentally fails its clinical mandate for that group. A robust debate exists regarding the ethical implications of using personalised nudges, derived from complex AI models, particularly concerning manipulation and infringement upon patient autonomy. However, an alternative viewpoint suggests that targeted health promotion, even if perceived as manipulative, can be justified as counter-manipulation. In this framework, the use of AI to encourage healthy choices acts against the widespread, manipulative commercial "illness promotion" inherent in the marketing of unhealthy products. The argument suggests that by neutralising pre-existing negative influences, manipulative health promotion may paradoxically enhance or restore the target’s autonomy. Strategic Recommendations and Future Outlook Strategic Recommendations for Development and Deployment Mandate Behavioral Science Integration: Future development efforts must formally begin and continuously cite established behavioural models (FBM, TTM) throughout the design and clinical validation process. This integration is the only way to systematically address the pervasive, long-standing challenge of adherence and ensures the methodological reproducibility of clinical success. Invest in Implicit Sensing and Interaction: Resources must be strategically channeled toward advanced sensor integration and AI inference engines that drastically minimise the need for explicit user interaction. By reducing the cognitive load required (increasing Fogg Ability), reliance on implicit data collection and ambient delivery of interventions will significantly reduce friction, which is the key determinant of long-term patient retention. Adopt "Ethics as Utility": Developers of AI-driven behavior change systems must recognize that algorithmic fairness is integral to clinical utility. Implementing rigorous bias auditing tools and promoting transparency in how the AI utilises demographic and behavioural data (eg, in the Knowledge Graph structure) is essential. This ensures that the system works reliably across all patient groups, protecting against systematic errors and maintaining clinical integrity. Future Trends: Digital Biomarkers and Integrated Care Pathways The digital health market is poised for continued robust expansion driven by the maturation and adoption of digital therapeutics. The next generation of innovation will center on the development and validation of sensor-based digital biomarkers. These markers track nuanced aspects of patient health and behaviour in both clinical care and research settings, ultimately leading to the approval of novel digital endpoints by regulatory bodies in the US and Europe. These biomarkers will provide objective, high-resolution data that traditional clinical measures cannot capture. The industry is converging toward the provision of comprehensive, integrated, end-to-end care pathways.Platforms utilising sophisticated AI, such as Biofourmis’ Biovitals, will increasingly leverage predictive analytics to deliver highly personalised interventions across complex acute and chronic conditions, establishing a new standard for precision medicine and population health management. This future state envisions technology that not only monitors disease but proactively predicts and intervenes against clinical exacerbations, transforming the ability of physicians to meet patients’ needs precisely where they occur. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

HealthTech C2B2C Business Models Explored Executive Summary: The Strategic Divergence of C2B2C and B2B2C in HealthTech The digital health ecosystem is witnessing the commercial maturation of intermediated business models, yet a critical distinction must be drawn between distribution channels and value origination. The business-to-business-to-consumer (B2B2C) model, characterised by partnerships between HealthTech companies and enterprise payers (employers, insurers), has become the default go-to-market strategy, primarily due to its ability to scale adoption and mitigate high customer acquisition costs (CAC). In contrast, the Consumer-to-Business-to-Consumer (C2B2C) model operates on the principle that the consumer (C1) is the source of the primary transactional asset: Patient-Generated Health Data (PGHD).While current HealthTech success stories are financially structured as B2B2C, their long-term strategic value is derived from this underlying C1-to-B data flow. The challenge inherent in C2B2C, unlike models in physical goods like automotive or electronics, is that the asset (health data) lacks an established, universally accepted valuation mechanism and carries immense regulatory risk. Expert analysis concludes that pure C2B2C is currently subsumed within the B2B2C distribution channel. Strategic investment should prioritise platforms that combine the scale and reliability of B2B2C revenue streams (enterprise contracts) with C2B2C architectural principles, such as verifiable, decentralised data governance and explicit consent management. This fusion is necessary to future-proof operations against evolving data ownership regulations and maximise the monetisation potential of patient outcomes data. Foundational Definitions and Market Context Delineating C2B2C, B2B2C, and D2C in HealthTech Understanding the landscape of digital health requires a precise definition of the primary operational models, which are differentiated by who pays, who benefits, and, crucially, who owns the data. The Direct-to-Consumer (D2C) model involves HealthTech companies selling subscriptions or services directly to individual patients or consumers. Classic examples include consumer wellness applications like Peloton or the Calm app. Historically, D2C models were highly utilised by early care delivery startups but eventually faced market saturation in digital marketing channels, leading to high and unsustainable Customer Acquisition Costs (CACs). The Business-to-Business (B2B) model involves companies selling products or software used exclusively by staff or organisations, such as providers or insurers. An example is a company that sells specialised hospital billing systems or claims-processing software to insurers, where the end user is internal staff rather than the patient. The B2B2C (The Dominant HealthTech Model) structure is defined by the HealthTech startup (B1) partnering with an intermediary organisation (B2), typically an employer, a self-insured health plan, or an insurer, to deliver services to the ultimate user (C). The B2 entity is the paying customer, providing the service as part of health coverage or workplace perks. Headspace Care, which offers mindfulness programs through corporate wellness benefits, and Maven Clinic, which distributes its FemTech solutions through employer contracts, are prominent examples. The C2B2C (The Data-Driven Model) structure, by definition, places the Consumer (C1) as the originator of the core asset. In established non-healthcare markets like electronics, the business (B) acts as a trusted intermediary, providing a margin by valuing and transacting a physical asset (C1 to C2). In HealthTech, the asset is the sensitive, regulated patient-generated health data (PGHD). The consumer provides this data (C1-to-B), which the business aggregates and licenses to a receiving party (C2/B2), such as a researcher, provider, or payer. An examination of the market reveals a paradoxical situation: while firms like Maven Clinic achieve strong financial success, reporting $268 Million in Annual Recurring Revenue (ARR) with 98% client retention through B2B2C contracts, the long-term, scalable strategic value is rooted in the continuous collection and analysis of usage data and clinical outcomes generated by the C1-to-B flow.Therefore, the commercial model is B2B2C, but the data engine is fundamentally C2B, creating a necessary convergence point between distribution and data architecture. Why B2B2C Became the Default Go-to-Market Strategy The prevailing B2B2C model is a direct consequence of addressing the systemic failures and limitations inherent in D2C models. The primary driver for the shift was the struggle of D2C startups with high and unsustainable CACs stemming from saturated digital channels. B2B2C allows companies to acquire members at lower costs and position themselves for value-based arrangements. This model leverages the vast distribution potential of employer-sponsored coverage, which reaches approximately 153 Million people in the US. Furthermore, a large portion of this market is self-funded (63% of covered workers in 2024, including 79% at large firms), creating a substantial, accessible channel for digital health solutions offered as benefits. The adoption hurdle associated with consumers being cautious about sharing personal medical data with new digital health tools is significantly mitigated in the B2B2C context. Employees often already trust their employer or payer, reducing the barrier of paying out-of-pocket and increasing adoption rates. Startups gain immediate access to a ready user base, valuable usage data, and reliable revenue streams, ensuring a more sustainable and scalable business structure than the D2C approach. The Unique Value Chain of C2B2C: Consumer Data as the Origin of Transactional Value The theoretical C2B2C model hinges on the premise that consumer data is the core transactional asset. The foundation for this model is the demonstrated willingness of consumers to share their health information. Survey data indicates that 63% of consumers are quite willing to share their personal health data if the value proposition is clear, such as ensuring their medical care is the highest quality possible. This willingness is being accelerated by regulatory and technological forces that are increasingly requiring data to be released from closed, centralised ecosystems. This shift transfers control to the consumer, allowing them to choose with whom and when they share their information.This regulatory impetus directly enables the C1-to-B link, transforming patient data from a static record managed by institutions into a dynamic, transferable asset. However, a notable gap exists between the conceptual C2B2C model and current operational reality: while C2B2C platforms are centred on C1 data ownership, successful B2B2C models primarily collect this C1 data and monetise the aggregated results for the B2 partner’s benefit (eg, improved workforce health or reduced long-term costs). The overarching challenge for pure C2B2C evolution is creating mechanisms that translate C1 control and contribution into direct economic value for the individual, beyond merely providing better quality care. The Dominant Paradigm: Analysing the B2B2C Model Stakeholder Value Proposition Analysis The success of the B2B2C model lies in its ability to deliver synergistic value to all three key stakeholders: the HealthTech startup (B1), the employer/payer (B2), and the end-user (C). For Startups (B1), the primary benefit is the combination of scale and financial stability. B1 gains immediate access to a ready user base and reliable revenue streams. This minimises the high customer acquisition costs inherent in D2C and provides large volumes of valuable real-world usage data needed to test features and validate efficacy. For Employers/Payers (B2), the value proposition centers on risk management and human capital strategy. These partnerships demonstrably improve workforce health, reduce long-term healthcare costs and enhance employee satisfaction. For large corporations like AT&T, extending benefits such as those provided by Maven Clinic to 125,000 employees serves as both a talent strategy and a market advantage, aiding retention and culture. For End Users (C), the model provides access to specialised, comprehensive virtual care solutions, such as femtech services across fertility, maternity, and menopause, often at no direct cost to the individual, delivered as a workplace perk. This access provides benefits like personalised care navigation and unlimited telehealth visits, removing financial and logistical barriers common in traditional care settings. Revenue Streams and Financial Metrics The financial engine of the B2B2C model is driven largely by enterprise contracts, offering predictability that supports high growth valuations. The most common and strategically preferred revenue model is Subscription or Per Member Per Month (PMPM) billing. This model generates predictable Annual Recurring Revenue (ARR), which is foundational for valuation and stable growth. Maven Clinic exemplifies this stability, achieving high client retention rates (98%) and significant financial scaling. A secondary, but emerging, model is Usage-Based Billing, seen in startups offering AI medical scribe services or platforms that charge based on the volume of data processed, such as documents stored or care directives generated. While usage-based billing appeals to consumers who prioritise transparency, it introduces forecasting difficulties for the business due to its lack of predictability compared to flat subscription fees. Furthermore, B2B2C companies are increasingly monetising Clinical Outcomes Data. Companies extract clinical data showing measurable impact, such as faster time to conception for fertility patients and use this validated data to negotiate contracts with employers or fertility benefit companies.This approach transforms the cost of the service into an investment, as B2 partners have a direct vested interest in adopting solutions that help reduce overall treatment costs, such as decreasing the need for multiple expensive IVF cycles. This conversion of C1-generated outcomes data into B2 cost savings forms the critical financial link between the consumer's activity and the business's profitability. Critical Challenges in B2B2C Adoption: Enrolment Marketing and Engagement Hurdles Despite the high-value enterprise contracts, the B2B2C model is not immune to consumer-facing challenges. Securing the enterprise contract is only the first hurdle; the second is achieving high enrolment and engagement among the "covered lives". This transition creates an Enrolment Chasm where the burden shifts from traditional D2C marketing spend to specialised enrolment marketing and patient acquisition strategies. Crucial to overcoming this is seamless Integration Necessity. For enterprise adoption to be streamlined, the digital health solution must integrate cleanly with existing HR platforms and benefits portals, such as Workday or ADP. This infrastructural integration is essential for verifying eligibility and streamlining the user onboarding process. Finally, the Messaging Duality required for B2B2C creates complex communications challenges. The company must simultaneously craft messaging that appeals to HR leaders, focused on outcomes, quantifiable ROI and cost reduction, while addressing busy employees with clear, tangible value from day one and firm assurances of privacy by design. The table below provides a comparative overview of the core digital health business models, highlighting how C2B2C is strategically positioned as a value originator, contrasting with B2B2C’s strength as a distribution mechanism. Comparison of Core Digital Health Business Models Model Primary Payer Primary User/Beneficiary Core Value Origin Key Scalability Challenge Direct-to-Consumer (D2C) Consumer (Individual) Consumer Service Access, Personal Wellness High Customer Acquisition Cost (CAC) Business-to-Business (B2B) Enterprise (Hospital, Insurer) Enterprise Staff/Internal Systems Efficiency, Claims Processing Lack of Direct User Engagement B2B2C (Employer-Driven) Enterprise (Employer, Payer) Employee/Member Distribution Scale, Reduced Adoption Barriers Enrollment and Ongoing Engagement C2B2C (Data-Driven) Intermediary Business (B) or Researcher C2 (Recipient) / Researcher (B2) Patient-Generated Health Data (PGHD) Trust, Regulatory Compliance, Interoperability The Evolution to Patient-Centric Value: C2B2C Architecture PGHD and the Consumer Data Explosion: Shifting Data Ownership Historically, the healthcare industry has been characterised by data-centric accumulation, where patient health information was fragmented and isolated within the centralised, siloed systems of individual health institutions. A patient might hold disparate records in Hospital A and Hospital B, with no immediate means for a provider in Hospital C to access both, limiting transparency and quality of care. The current industry transformation emphasises a shift toward patient centric personalised care, leveraging advanced data analysis and Artificial Intelligence (AI) to transform large datasets into actionable, tailored insights. This movement recognises that maximising the potential of data requires prioritising the patient's needs. Empowering patients with 24/7 access to their records facilitates continuous monitoring, simplifies chronic disease management, reduces medical errors associated with paper records, and enables patients to make more informed decisions about their conditions. This control is the vital mechanism allowing C1 to initiate the C2B transaction. The Role of Decentralisation (Web3 and Blockchain) in Empowering C1 For the C2B2C model to achieve its promise of patient-controlled data, new architectural foundations are necessary. The emerging era of Web3, the decentralised web, offers a transformative approach, particularly in how patient data are governed, accessed, and valued. Decentralisation, often facilitated by blockchain technology, is positioned as the architectural solution to enhance patient data access, control, privacy, and value. This technology directly addresses the problems of siloed data storage and centralised points of failure, which are susceptible to breaches. Platforms based on this concept, such as MediLinker, have been developed to provide decentralised health information management, improving interoperability and data protection. The deployment of decentralised technology serves as the trust enabler required for sensitive health transactions. In a C2B2C model, the intermediary business (B) must provide an ironclad guarantee that it handles the sensitive asset (PGHD) with integrity. Decentralization offers an immutable, verifiable mechanism for demonstrating data control and explicit consent to the consumer (C1). This fundamental technological shift redefines the role of the "B" entity from a mere centralised data collector to a compliant governance and transaction layer, solving the trust deficit inherent in traditional centralised data systems. Monetisation Strategies for Patient-Generated Data Monetisation of PGHD within the intermediated health ecosystem generally follows two pathways. The current dominant approach is the B2B Data Licensing Model, where the HealthTech platform (B) aggregates, anonymises, and analyses clinical outcomes and usage data, licensing these valuable insights to external partners (B2). These B2 partners include pharmaceutical researchers, payers, and employers seeking to validate health intervention effectiveness or identify new risk cohorts. This strategy allows the business to extract value from C1's data on a large scale while shielding the enterprise client from the complexity of individual consent management. The anticipated Future C1-to-C2/B2 Payment Models involve mechanisms that directly compensate C1 for their data contribution. This model is underpinned by regulatory shifts, such as the proposed European Health Data Space, which introduces permit-based systems through Health Data Access Bodies (HDABs) allowing for the secondary use of data for research, algorithm training, and evaluation. These systems could eventually allow usage-based payment models where the consumer (C1) is rewarded directly or indirectly for granting permission for their anonymised data to be used by researchers (C2/B2), fully realising the economic potential of the C2B2C framework. Technology, Interoperability and Infrastructure Requirements Mandatory Integration with Enterprise Ecosystems The operational success of scaling digital health solutions relies on mandatory integration across multiple enterprise systems. For the dominant B2B2C channel, seamless integration with human resources (HR) systems, such as Workday and ADP, is non-negotiable for streamlining member acquisition, ensuring eligibility validation, and simplifying the onboarding journey. Beyond HR integration, there is a powerful strategic necessity for integrating with Payer-Provider Collaboration platforms. Collaborative relationships between payers and providers significantly enhance efficiency and effectiveness in the healthcare system. Utilising a joint payer-provider platform facilitates real-time data sharing, reduces administrative "red tape" associated with specialist referrals, and enables both parties to prioritise preventative care initiatives. This convergence creates a major opportunity for C2B2C models. These joint payer-provider platforms form a compliant, high-value "B" layer. A C2B solution can integrate PGHD (C1) directly into these joint decision-making platforms (P-P) for optimised care delivery (C2/B2), effectively creating a C2B2P-P model that leverages existing enterprise infrastructure for maximized clinical and financial impact. Rewarding quality treatment over high service volumes becomes possible when data flows are streamlined and aligned between these parties. FHIR Adoption: Opportunities for Seamless Data Exchange and Implementation Challenges Fast Healthcare Interoperability Resources (FHIR) stands as the essential standard for achieving seamless data exchange in modern HealthTech. FHIR adoption ensures cleaner data flows, interoperability with wearables, Electronic Health Records (EHRs), and third-party services, allowing the C2B solution to function effectively within diverse and fragmented digital ecosystems. Tighter integration with existing HR stacks is also supported by standards like FHIR, enhancing personalisation powered by machine learning (ML). However, the transition to FHIR is fraught with implementation challenges: Steep Learning Curve: FHIR's resource-based model requires significant technical expertise and development time, challenging teams without specialised prior experience. Increased Development Costs: The complexity mandates sophisticated development and testing procedures, leading to increased costs and longer implementation timelines. Interoperability and Data Mapping Friction: Despite its purpose, FHIR's resource model can still introduce interoperability challenges, as different systems may interpret resources inconsistently. The complex structure requires extensive, time-consuming, and error-prone data mapping and transformation. Building Scalable, Secure and Patient-Centric Digital Platforms The technology infrastructure must be designed for both security and massive scale. Scalable architectures are mandatory to handle potential sudden spikes in usage typical of the B2B2C mass adoption channel. Furthermore, a mobile-first, accessible design and intuitive onboarding process are fundamental product instincts necessary to drive high adoption and engagement. Security is the foundational layer upon which trust and compliance are built. Secure cloud infrastructure that meets stringent regulatory requirements like HIPAA and GDPR is essential, mandating strong encryption, precise access controls, and immutable audit logs to protect sensitive health data. While patient-facing platforms offer advantages, such as monitoring and controlling patient records and 24/7 access to information, they also introduce specific disadvantages. Patients may experience information overload and struggle to interpret or use the vast amount of clinical data provided. Moreover, for patients who lack access to technology or are uncomfortable with the internet, the digital divide can limit access. Most significantly, if proper security measures are not meticulously maintained, patient portals that store sensitive information pose a constant risk of data breaches and security concerns. Technical Interoperability Requirements for Platform Success Category Specific Requirement/Standard Strategic Purpose Associated Challenge Data Exchange FHIR (Fast Healthcare Interoperability Resources) Standardised, real-time data flows between systems (EHRs, Payers) Steep learning curve, increased development complexity, data mapping Enterprise Integration API integration with HR systems (e.g., Workday, ADP) Critical for seamless B2B2C adoption, onboarding, and eligibility validation Ensuring long-term maintenance and compliance of third-party APIs Patient Control Blockchain/Decentralised Architecture Enhancing patient data ownership, privacy, and verifiable consent for C1-to-B trust Nascent technology, scaling hurdles, regulatory uncertainty in monetisation Data Analytics Machine Learning (ML), Visualization Tools (Looker, Tableau) Transforming raw C1 usage data into actionable outcomes (ROI) for B2 (employers) Ensuring data privacy is maintained during ML processing and reporting Regulatory and Ethical Imperatives for Data-Driven Models Global Compliance Requirements: Detailed Comparison of HIPAA vs. GDPR Scaling an intermediated HealthTech model requires navigating complex, and often contradictory, global compliance frameworks. The two most critical are the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the European Union’s General Data Protection Regulation (GDPR). HIPAA is specific to the U.S., focusing solely on the privacy and security of Protected Health Information (PHI). It traditionally allows for implied consent for standard healthcare operations. GDPR, in contrast, applies globally to any organisation handling the personal data of EU residents. Its scope is significantly broader, encompassing all personal data, including health information, names, and IP addresses.GDPR mandates explicit, granular consent for data use, emphasises data minimisation, and requires breach notification within 72 hours. Crucially, for any platform aiming for global scalability, GDPR effectively establishes the minimum standard for privacy and consent. The penalties for non-compliance are severe up to €20 million or 4% of global annual revenue dramatically outweighing HIPAA’s capped fine structure ($1.5 million per violation per year). This financial exposure forces digital health companies to adopt a "privacy by design" approach globally, ensuring stricter privacy controls from the earliest stages of product development. Achieving Legal Patient Consent Management (The Single Source of Truth) The C2B2C model fundamentally relies on the C1 entity willingly and knowingly authorizing the transaction of their data. This necessitates an evolution beyond traditional implied consent systems toward mandatory explicit consent, particularly in light of GDPR's stringent requirements. To manage these complex permissions across multiple stakeholders, platforms, and geographies, sophisticated Consent Management Platforms (CMPs) are required. Tools that connect consent preferences across third-party suppliers, channels, and stakeholders, creating a real-time, "single source of truth" for patient preferences, are essential for maintaining adherence to regulations like HIPAA and GDPR. Furthermore, regulatory bodies are actively creating mechanisms to standardise the secondary use of health data. Initiatives like the European Health Data Space, operating via new Health Data Access Bodies (HDABs), aim to create a legitimate, permit-based system for sharing health data for purposes such as scientific research, training AI algorithms, and evaluating platform efficacy. This regulatory standardisation is vital for professionalising the C2B data market. Mitigating Data Risks and Liability in Decentralised Systems Even with advanced security, centralised patient data systems carry inherent risks, including the vulnerability of data breaches. Decentralisation aims to mitigate this by eliminating centralised points of failure through blockchain technology. However, empowering C1 with greater access introduces new forms of liability. Increased patient access to complex or fragmented health information can lead to unnecessary patient concerns regarding their diagnosis or treatment plan, and platforms may face malpractice liability concerns related to data accuracy, interpretation of records, or remote monitoring functionality. To ensure trust, privacy by design must be a non-negotiable core principle of the product architecture.This entails the mandatory use of robust security features, including encryption, rigorous access controls, and auditable logging, that comply with global data protection mandates. Comparative Analysis of Core Regulatory Frameworks Feature HIPAA (USA) GDPR (EU/UK) Implication for C2B2C HealthTech Scope of Data Protected Health Information (PHI) All Personal Data (including health data, IP addresses) Global platforms must adopt the broader, more restrictive GDPR scope. Consent Standard Implied consent often sufficient for care operations Requires Explicit, Granular Consent for processing and secondary use C2B link (data acquisition) demands a robust CMP ensuring explicit C1 authorization. Breach Notification Generally 60 days Mandated notification within 72 hours Stricter operational urgency and liability exposure under GDPR. Maximum Penalties Up to $1.5M per violation per year (Capped) Up to €20M or 4% of Global Annual Revenue (Uncapped based on revenue) Non-compliance risk is exponentially higher for globally scaling enterprises. Strategic Outlook and Recommendations Competitive Strategy: Leveraging C2B2C Data Assets to Gain B2B2C Traction The strategic path for digital health ventures involves accepting the B2B2C model as the necessary distribution channel while simultaneously developing the underlying C2B model as the source of sustainable competitive advantage. Success is measured by the ability to generate and leverage clinical outcomes data derived from patient usage (C1). Startups must utilise the high volume of C1 usage data to prove measurable impact and ROI to B2 partners (employers/insurers). High engagement data, such as Maven Clinic’s 95% enrolment rate at Snap Inc. and high average provider visits per member, serves as the primary sales pitch, validating the efficacy and uptake of the solution. The most successful strategy is not to compete with the dominant B2B2C channels, but to integrate C2B architectural principles, focused on verifiable consent and data control, into the B2B2C platform, enhancing compliance credibility and delivering superior outcomes reporting to the enterprise client. Future Trends: Payer-Provider Collaboration and Joint Platforms The industry trend toward value-based care is driving increasingly strong Payer-Provider Collaboration. Joint payer-provider platforms that facilitate real-time data sharing and align incentives away from high service volumes toward quality outcomes are crucial for preventative care and systemic efficiency. This dynamic suggests that the most effective and efficient future models will align the C2B data origin with this joint enterprise infrastructure. This model, potentially described as C2B2P-P (Consumer -> HealthTech Business -> Payer/Provider Joint Platform), leverages the scale and compliant nature of the Payer-Provider environment for seamless clinical integration and decision support. By channeling PGHD through this robust intermediary layer, companies can achieve both market scale and deep clinical impact, accelerating the shift toward personalized medicine driven by real-world evidence. Actionable Recommendations for Investment and Platform Development Based on the analysis of regulatory risks, market adoption dynamics, and technological requirements, the following strategic actions are recommended for investing in or developing HealthTech platforms: Prioritise Trust Infrastructure and Consent Management: Investment must focus heavily on developing or adopting robust, auditable Consent Management Platforms (CMPs). These systems must function as the single source of truth for granular patient preferences (C1), mitigating the existential regulatory risk posed by GDPR and HIPAA non-compliance. This infrastructure is the foundation of the C2B relationship. Mandate a Structured FHIR Maturity Roadmap: While FHIR implementation presents technical complexity (steep learning curve, high cost) , it is essential for long-term survival. Development resources should adopt a phased approach, prioritising FHIR capabilities necessary for high-value data exchange with payers and providers, which is crucial for achieving alignment in value-based care and facilitating the C2B2P-P model. Pilot Decentralised Governance Models: Allocate research and development capital to pilot decentralised architectures (e.g., blockchain/Web3). This investment should focus specifically on managing patient consent, data access permissions, and immutable audit trails, rather than attempting full EHR replacement. This positions the company as a leader in patient-centric control, establishing a significant long-term competitive moat built on verifiable trust. Enforce Enrolment and Engagement Expertise: Recognising that B2B2C success hinges on consumer adoption, companies must require and invest in specialised enrolment marketing expertise.The technical excellence of the solution is rendered irrelevant if the target user base (C) is not effectively reached, acquired, and engaged through seamless integration with enterprise systems. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

UK HealthTech M&A Market: What's Hot and What's Not in 2025 and looking ahead into 2026 Executive Summary: A Cautious but Resilient Rebound Defined by Bifurcation The UK HealthTech mergers and acquisitions (M&A) market in 2025 is characterised by a "cautious yet discernible rebound". While global digital health funding has seen a decline, the European market, particularly within the UK, has demonstrated remarkable resilience, defying global trends with a significant surge in deal activity. This momentum is not uniform, however; it is marked by a profound bifurcation that separates the market into two distinct categories. A "flight to quality" is directing a concentrated flow of capital towards high-quality, proven assets. The sub-sectors commanding the highest interest and premium valuations are those at the forefront of technological and operational transformation, particularly those focused on artificial intelligence (AI) and advanced analytics. These companies, with their strong fundamentals and clear value propositions, are attracting intense competition from both strategic and financial buyers. Conversely, the market is also witnessing a surge in distressed M&A activity. A post-pandemic funding pullback and persistent economic pressures have created a class of smaller, unprofitable startups with unsustainable burn rates. These firms are increasingly being acquired at "bargain-basement valuations" as a survival mechanism, rather than a growth strategy. This dynamic reshapes the ecosystem by consolidating power in fewer, stronger hands. Looking ahead to 2026, this bifurcated landscape is expected to persist. The market's fundamental drivers, such as the UK government's ambitious £10 Billion NHS digital transformation plan and the immense private equity "dry powder" available for deployment, will continue to fuel a robust M&A environment. The focus will intensify on companies with proven clinical validation and scalable, defensible business models, making M&A the primary and most pragmatic exit route for innovation as the IPO market remains challenged. The 2025 UK HealthTech M&A Landscape: A Cautious but Resilient Rebound Market Performance and Deal Flow The first half of 2025 has established a clear trajectory for the UK and broader European HealthTech M&A markets. The European digital health funding landscape, in particular, saw an impressive 52% year-on-year increase in the first half of the year, reaching $3.4 Billion across 182 deals. This performance is particularly noteworthy because it runs contrary to the global digital health funding trend, which experienced a 13% year-on-year decline over the same period. The UK's HealthTech sector has been a key contributor to this regional strength, with the UK MedTech market alone projected to reach £15.7 Billion in 2025, and a steady growth forecast to £20.5 Billion by 2030. Overall, deal volume for HealthTech M&A is on pace to exceed 2024's total. In the first half of 2025, there were 277 deals in HealthTech, which projects a full-year total well above the 467 deals recorded in 2024.Similarly, disclosed deal value is on a growth path, reaching $10.3 Billion in H1 2025, on pace to surpass the 2024 total of $19.2 Billion. However, it is important to note that only a small fraction (11%) of transactions disclose deal values, suggesting the actual value is significantly higher. The resilience of this market is largely attributed to a concentration of capital in fewer but larger transactions. The first half of the year saw four mega deals of over $1 Billion globally. In Europe, a handful of large "mega-deals" valued at $100 Million or more drove a significant portion of the total venture capital investment, with seven such deals accounting for 56% of the region's total investment. This trend signifies a shift away from a "spray and pray" approach towards a more selective and strategic model of "high-conviction investment". The divergence between the European market's performance and the global trend is a key indicator of the UK's unique value proposition. The UK's strong innovation capacity, supported by a clear governmental commitment to digital transformation, provides a more stable and predictable environment for scaling HealthTech solutions compared to other regions. The NHS's long-term strategic plans and substantial investment create a powerful market signal and a ready customer base, which reduces regulatory uncertainty and makes the region a highly attractive destination for capital. This institutional demand and strategic clarity serve as a significant tailwind that helps to insulate the UK HealthTech sector from broader global macroeconomic pressures. Macroeconomic and Financial Drivers The robust deal activity in 2025 is fueled by a confluence of favorable macroeconomic and financial factors. A significant driver is the immense amount of "dry powder", unspent capital, held by private equity (PE) firms. With trillions of dollars available, PE firms are eager to make deals and are actively pursuing acquisitions, which increases competition for desirable assets. The anticipated and realised interest rate cuts in 2025 have also played a crucial role. The expectation of falling interest rates makes financing M&A deals cheaper, further fuelling acquisition activity and helping to bridge the wide bid-ask spreads that have constrained the market in previous years. This decline in debt cost boosts the multiples that buyers are willing to pay, thereby reigniting deal flow. An increasingly important factor in deal financing is the growth of private credit. The retreat of traditional banks from non-investment grade leveraged lending has created a gap that has been filled by a maturing private credit market, which has become a "critical and permanent solution". The flexibility and certainty of execution offered by private credit are particularly appealing to dealmakers operating in volatile market conditions where full controlling-interest buyouts are less frequent. This synergistic relationship between private equity and private credit is providing the necessary capital to propel the rebound in M&A activity. What's Hot: The Drivers of Premium Valuations The "hot" sub-sectors in the UK HealthTech M&A market are defined by their ability to address fundamental challenges within the healthcare system, such as cost reduction, efficiency, and access to care. These companies are commanding premium valuations due to their proven technologies and alignment with the industry's strategic priorities. The AI and Advanced Technology Revolution Artificial intelligence (AI) has emerged as the single most dominant force in HealthTech M&A, moving from a novel tool to a "strategic imperative". The UK government's commitment to making the NHS the "most AI-enabled care system in the world" provides a powerful and well-funded tailwind for this sector. AI is being applied across the healthcare value chain, transforming diagnostics, drug discovery and patient care through predictive analytics and imaging AI. The widespread adoption of technologies such as large language models (LLMs) and purpose-built models is shifting the industry from augmenting human capabilities to enabling "autonomous execution". Companies with proprietary AI algorithms, scalable platforms, and proven solutions are attracting heightened interest from buyers and commanding the highest multiples in the market. While the average revenue multiple for HealthTech companies is between 4-6x, firms with proven AI solutions are seeing multiples rise to 6-8x or more, as buyers pay a premium for innovation and future revenue potential. This is because AI's ability to cut costs and improve patient outcomes directly aligns with healthcare's biggest challenges. A key factor amplifying the appeal of UK-based AI firms is the proactive regulatory environment. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has taken a leading role in this area by becoming the first country to join the new HealthAI Global Regulatory Network. The MHRA's "AI Airlock," a regulatory sandbox for AI medical devices, allows companies to test new tools under regulatory oversight before wider NHS roll-out. This action provides a clear regulatory pathway that reduces risk for acquirers and boosts confidence, which in turn lifts multiples by 0.5-1x for compliant firms and is a critical driver of M&A premiums. Strategic Consolidation and the "String of Pearls" Strategy Strategic consolidation is a core driver of M&A activity, with healthcare organisations merging to enhance efficiency, gain market share, and address challenges such as workforce shortages and regulatory complexities. This consolidation is often executed through a "string of pearls" strategy, where larger healthcare players, including hospitals and big Pharma, acquire smaller, innovative companies to fill strategic gaps and enhance their core platforms. An example of this is the acquisition of ImplantBase by Surgimate to create a unified platform for surgical management, aiming to enhance efficiency from pre-op to post-op procedures. This trend has a significant ripple effect that creates M&A opportunities in ancillary sectors. When hospital systems merge, they often have incompatible legacy systems, which creates cybersecurity vulnerabilities that hackers can exploit. This heightened need for data security is stimulating M&A deals among tech companies that can provide effective cybersecurity and IT services to the newly formed, consolidated entities. A deal exemplifying this is the merger of IT and cybersecurity managed service provider Abacus Group with healthcare IT services company Medicus IT in H1 2025. The Shift to Value-Based Care and Patient-Centric Models The healthcare industry's ongoing shift from a fee-for-service model to a value-based care model, which prioritizes patient outcomes over volume, is a significant driver of M&A. Technologies that enable this shift, such as remote monitoring, population health analytics, and chronic disease management platforms, are gaining significant traction with payers and providers. Companies aligned with value-based care are attracting premiums, with multiples climbing to 5.5-7x revenue, as buyers are willing to pay more for technology that delivers measurable cost savings and improved patient outcomes. Telehealth, a cornerstone of this shift, has matured beyond its pandemic-era boom into a stable sub-sector. It is evolving beyond standalone platforms into integrated, hybrid care models. While growth has slowed from its peak, adoption remains strong, and profitable firms with hybrid offerings are sustaining high valuations, often in the 5-7x revenue range. The acquisition of the UK startup Surgery Hero by the US-based telehealth company Sword Health illustrates the continued strategic interest in this space, as buyers seek to improve postoperative outcomes through digital solutions. The Resurgence of Behavioural Health Investor interest in behavioural health platforms, particularly for autism, addiction, and outpatient psychology, has reignited in 2025. This sub-sector saw a jump in deal flow of over 35% year-on-year in the first quarter, with autism deals doubling to their highest quarterly count since 2020. This trend is driven by surging societal demand and a renewed investor focus on these high-growth, high-impact areas. Valuation Multiples and Market Trends. Metric/Trend Q1-Q2 2025 Data Key Context Average Revenue Multiple (HealthTech) 4-6x; Q1 average at 4.8x A slight decrease from the 2023 peak but still notably higher than the 3.5x average for all technology companies, indicating sustained demand. Premium Revenue Multiple (AI-driven) 6-8x revenue or more Buyers are paying a significant premium for companies with proven AI solutions and strong IP, reflecting AI's strategic imperative in healthcare. Distressed Revenue Multiple (Unprofitable) 1-3x revenue A "buyer's market" for distressed assets, creating an opportunity for opportunistic acquisitions at a discount. EV to EBITDA Multiple (Profitable) 10-14x as of June 2025 A slight increase from 2024, reflecting cautious optimism for profitable, established entities. What's Not: The Headwinds and Challenges Despite the overall market rebound, significant challenges persist, creating a class of companies and sub-sectors that are struggling to attract investment and are experiencing compressed valuations. The Surge in Distressed M&A A key feature of the 2025 HealthTech M&A landscape is the surge in distressed M&A activity. This trend is a direct result of the "economic squeeze and funding drought" that has impacted the sector. Following a post-pandemic funding pullback, venture capital has tightened, leaving "cash-hungry startups" with unsustainable burn rates and over-leveraged balance sheets. This forces many firms to seek M&A as a "survival mechanism" rather than a growth strategy. This financial distress is creating a buyer's market. Distressed firms are trading at steep discounts, with multiples sometimes as low as 1-3x revenue compared to 5-10x for healthier peers. By year-end 2025, distressed deals could comprise 20-30% of HealthTech M&A activity , presenting a significant opportunity for opportunistic buyers, particularly private equity firms, to acquire innovative technology at "cut rates". The increase in distressed M&A, while boosting deal volume, can have a detrimental effect on the broader innovation ecosystem. When early-stage, cash-strapped companies are absorbed or shut down before they can fully mature and prove their value, it can stifle the pipeline of future breakthroughs needed by the NHS and other healthcare systems. This dynamic highlights a paradox: a market that is active but also potentially less innovative due to the financial pressures on early-stage firms. UK Specific Bottlenecks UK-based MedTech and HealthTech innovators face specific, structural barriers that impede their growth and make it more difficult to secure domestic investment. UK Specific Market Headwinds and Their Impacts Headwind Cause & Description Impact on M&A & Innovation Fragmented NHS Procurement The existence of 42 Integrated Care Systems (ICSs), each with its own priorities and adoption processes, makes it a "slog" for firms to scale their solutions nationally. Deters investors by introducing significant market complexity and delays patient access to innovations due to a lack of a clear, unified pathway to understanding demand. Regulatory Hurdles The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is perceived by innovators as "under-resourced" and "difficult to navigate." Creates uncertainty that can cap multiples and deter deals, particularly for early-stage companies lacking a clear regulatory pathway for their technology. Domestic Funding Drought Following the global VC pullback, UK SMEs are experiencing a decline in domestic Series B+ investment. Forces companies to seek funding from abroad and makes them more vulnerable to distressed acquisitions at reduced valuations. Brexit Fallout The lingering effects of Brexit continue to create uncertainty regarding trade and talent mobility, particularly for firms reliant on cross-border operations. Adds a layer of complexity and risk to due diligence, which can impact investor sentiment and depress valuations for affected companies. The Decline of Certain Sectors A notable trend in 2025 is a decline in deal volume within the pharma and life sciences sector, which has historically been a superstar of M&A activity. Private equity firms, in particular, are pulling back from areas like contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs) because many of these businesses, acquired in the 2021-2022 cycle, have underperformed expectations. This shift is not a lack of interest in the industry as a whole, but rather a re-evaluation of the investment thesis. The initial boom in these sectors was based on an assumption that large pharmaceutical companies would continue to outsource non-core functions. However, the reality has proven more complex, with some pharmaceutical companies showing discomfort with outsourcing and a global pullback in drug research. As a result, private equity firms are now shifting their focus toward a more direct involvement in the profits from selling drugs and are "all looking for the next Ozempic". This maturation of their approach reflects a move away from services and toward high-impact, direct-profit opportunities, which are often technology-enabled, as seen in the rising interest in biosimilars. The Driving Forces: Financing and Policy Dynamics The Evolution of Private Equity's Role Private equity firms are the primary engine of M&A activity in the UK HealthTech sector. The PE playbook in 2025 has shifted from a "spray and pray" approach to a more disciplined model of "concentrated, high conviction investment". With immense dry powder to deploy, PE firms are under pressure to find high performing assets. The target companies they now prioritise have strong recurring revenue models, proven clinical efficacy, and defensible IP. A common strategy is the "buy-and-build" approach, which is well-suited to the fragmented UK HealthTech landscape. In this model, a PE firm acquires a platform company and then makes a series of smaller "bolt-on" acquisitions to enhance its core capabilities, expand its geographic reach, and achieve economies of scale. To address the long investment horizons often required by HealthTech's complex regulatory and adoption cycles, PE firms are also increasingly utilising continuation funds to "hold and grow" high-performing "crown jewel" assets beyond the typical 10-year fund life. The Impact of UK Government Policy The UK government's long-term strategic initiatives are a major catalyst for M&A activity, providing a clear and well-funded market direction. The government's 10-year health plan aims to make the NHS the "most AI-enabled care system in the world" and has committed up to £10 Billion to digitise the NHS by 2028-29. This substantial investment creates a powerful market signal and a stable customer base for HealthTech companies. Key elements of this plan, such as transforming the NHS App into a "digital front door" and creating a "single patient record," are directly creating institutional demand for solutions in patient engagement, data analytics and care coordination. This alignment between government policy and technological innovation reduces market risk for investors and makes the UK an attractive destination for capital. Innovative Deal Structures To bridge persistent valuation gaps and navigate market uncertainty, dealmakers are increasingly turning to flexible and creative deal structures. One such structure is the earn-out, where additional consideration is paid based on future performance milestones. While prevalent in life sciences M&A, with over 90% of biopharma deals including them, the achievement rate is low, with only about 25% of earn-outs actually paid out. This highlights a growing tension between sellers, who see earn-outs as a way to secure a higher valuation, and buyers, who are increasingly seeking robust protections to mitigate litigation risk. Another key trend is the growth of private credit as a source of financing. As traditional lenders have pulled back from leveraged lending, private credit funds have filled the void, becoming a "critical and permanent solution" for financing deals. This provides borrowers with greater flexibility, certainty of execution and more tailored funding solutions than traditional syndicated lending, which is particularly appealing to both financial and strategic acquirers in a competitive market. Outlook for 2026: Navigating a Bifurcated Future Forecast for Deal Activity and Valuations The outlook for the UK HealthTech M&A market in 2026 remains robust. The underlying drivers of the market, the ongoing need for innovation, efficiency, and better patient care are fundamental and not subject to short-term cyclical fluctuations. The market is expected to remain active, with continued M&A activity driven by both strategic and financial buyers. The market bifurcation seen in 2025 will likely persist. High-quality assets will continue to command premium valuations, with AI-enabled and clinically validated firms maintaining multiples in the 6-8x revenue range and higher. The UK digital health market's projected compound annual growth rate (CAGR) of 22.8% from 2025 to 2030 provides a strong, long-term macroeconomic rationale for this trend. Conversely, the distressed segment will continue to see opportunistic acquisitions at depressed valuations, as capital remains focused on proven winners. Key Themes for the Year Ahead AI's Inevitability: AI will move beyond being a trend to becoming a fundamental necessity. The focus for buyers will shift from acquiring companies experimenting with AI to acquiring those with proven, working technology that can be integrated to achieve a competitive edge.The UK's proactive regulatory stance on AI will further reduce risk for acquirers and incentivise investment in compliant solutions. The Primacy of Clinical Validation: The "flight to quality" signifies a new level of maturity in the market. Investors will no longer be captivated by aggressive expansion at all costs but will instead prioritise companies that can demonstrate "clinically validated datasets, clear reimbursement pathways and robust, defensible AI pipelines". Speculative ventures with unproven models will continue to struggle and will be relegated to the distressed category. Continued Consolidation and Ecosystem Reshaping: The market will continue to reshape as power consolidates in fewer, stronger hands. Larger HealthTech players and Integrated Care Systems (ICSs) will continue to scoop up distressed assets to bolster their digital capabilities. This will create a streamlined ecosystem with a more concentrated pool of dominant players. Strategic Recommendations for Market Participants For Sellers: To command a premium valuation, focus on demonstrating a clear path to profitability, securing recurring revenue streams, and obtaining clinical validation for your technology. Prepare for due diligence by ensuring all financial and compliance records are meticulous and accessible, as this signals maturity and reduces deal friction. For Buyers: Leverage the bifurcated market by being opportunistic. For high-growth assets, be prepared to compete with strategic buyers and PE firms with large capital reserves. For distressed assets, conduct thorough due diligence to ensure the target's underlying technology and talent are truly valuable and not just a symptom of operational overreach. Consider flexible deal structures, like private credit, to gain an edge in competitive situations. For Investors: Align investment theses with the UK government's long-term digital transformation plans, as this provides a stable, long-term market tailwind. Focus on companies that enable the shift to value-based care and can demonstrate a quantifiable impact on patient outcomes and cost savings. Consider opportunities in the maturing biosimilars market, which is now attracting significant PE interest due to its high-margin potential and technology-enabled development pathways. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

MHRA establishes UK AI Healthcare Regulation Commission for Ambient Voice Technology and AI Tools The UK National Commission on the Regulation of AI in Healthcare: An Expert Analysis Executive Summary The UK National Commission on the Regulation of AI in Healthcare has been established as a critical, non-statutory advisory body by the Medicines and Healthcare products Regulatory Agency (MHRA) to address the growing disparity between the rapid pace of artificial intelligence (AI) innovation and a legacy regulatory framework. Its mandate is to review existing regulations and provide a comprehensive set of recommendations for a new, rewritten rulebook for AI in healthcare, which is expected to be published next year. This strategic initiative is designed with a dual purpose: to accelerate the safe and effective adoption of cutting-edge AI tools within the National Health Service (NHS) and to position the UK as a global leader in responsible health technology regulation, thereby attracting significant international investment. The Commission's work is not merely a bureaucratic exercise; it is a direct response to a series of foundational challenges unique to AI. These include the "black box" problem, which erodes trust and complicates accountability; algorithmic bias, which can perpetuate and amplify existing health inequalities; and the difficulty of regulating continuously learning, or adaptive, AI systems that evolve after they are deployed. While the MHRA has already begun addressing these issues through initiatives like the AI Airlock sandbox and various change programmes, the Commission's role is to formalise these efforts into a coherent, national framework. The analysis further reveals that the success of this regulatory reform will depend on addressing broader systemic barriers to adoption, such as fragmented IT systems, complex procurement processes, and a general lack of AI literacy within the NHS workforce. By tackling both the regulatory and operational hurdles, the UK aims to build a comprehensive ecosystem that fosters innovation, ensures patient safety, and delivers tangible benefits for the health service. Source: https://www.gov.uk/government/groups/national-commission-into-the-regulation-of-ai-in-healthcare Introduction: The UK's Strategic Mandate for AI in Healthcare The National Imperative for Digital Transformation The establishment of the UK National Commission on the Regulation of AI in Healthcare is a foundational component of the government's broader strategic vision for digital transformation. It is framed within the context of the government's "Plan for Change" and the NHS's ambitious agenda to integrate technology to improve patient outcomes and operational efficiency. This is not a theoretical exercise; AI is already making a substantial difference across the NHS. For instance, AI-supported diagnostics have been shown to reduce diagnostic errors by 42% in some hospitals. Furthermore, AI tools are currently in use in 100% of England's stroke units to analyse brain scans, assisting doctors in making rapid and informed treatment decisions. The demonstrated efficacy of these early applications provides the clear and urgent rationale for a regulatory framework that can accelerate the safe adoption of even more transformative technologies. The Critical Gap: Innovation Outpacing Regulation The primary problem that the Commission is tasked with solving is the disjunction between the blistering pace of AI innovation and the limitations of the existing regulatory framework. Lawrence Tallon, the Chief Executive of the MHRA, has explicitly articulated this challenge, stating, “We want regulation of AI in healthcare to move at the pace of innovation”. The current "regulatory rulebook" was predominantly designed for static medical devices, such as pharmaceuticals and hardware, and is not equipped to handle the unique characteristics of AI systems. Unlike a pill or a fixed piece of hardware, the performance of an AI system can change over time and may vary across different patient populations, presenting novel challenges for oversight and assurance.This regulatory uncertainty is currently holding back a range of promising technologies, from administrative assistants to diagnostic tools. The Commission's purpose is to resolve this specific bottleneck, creating a clear and predictable pathway that fosters innovation while maintaining the highest standards of patient safety and public confidence. The UK National Commission: Mandate, Structure, and Immediate Focus Establishment and Mandate The UK National Commission on the Regulation of AI in Healthcare has been established by the MHRA as a non-statutory advisory body. Its central mandate is to advise the MHRA on how to "re-write the regulatory rulebook on AI in healthcare". The ultimate output of this work will be a new regulatory framework set to be published in 2026. A key step in this process will be a "call for evidence" that is expected to invite contributions from a diverse range of stakeholders, both within the UK and internationally, to help shape the Commission's recommendations and address "the most pressing challenges" in AI regulation. The MHRA has committed to acting on these recommendations, which will support the digital transformation of the NHS and advance the UK's ambition to become a global hub for health tech investment. Composition and Leadership The composition of the Commission is a strong indicator of the breadth and depth of its mandate. It intentionally brings together a multidisciplinary group of experts from global tech firms, such as Google and Microsoft, alongside leading clinicians, researchers, and patient advocates. This diverse representation is a deliberate strategy to build a regulatory framework that is "trusted by the public and health professionals". The leadership of the Commission further reinforces this balanced approach. It is chaired by Professor Alastair Denniston, a practising NHS clinician and head of the UK's Centre of Excellence in Regulatory Science in AI & Digital Health (CERSI-AI). Serving as Deputy Chair is the Patient Safety Commissioner, Professor Henrietta Hughes, who has emphasised the critical importance of incorporating patients' views to ensure the safe and equitable use of AI. Immediate Priorities and Tangible Goals The Commission's work is not abstract; it is focused on providing immediate "regulatory clarity" for specific technologies currently stalled by uncertainty.The initiative is designed to unblock innovation and enable the NHS to get quicker access to a range of proven AI tools. The report highlights three key, tangible goals for the Commission's initial review: AI Assistants for Clinicians: The Commission will immediately review technologies like "Ambient Voice Technology" that can reduce administrative burden for doctors by automatically taking notes. Early tests have already shown that this technology can allow clinicians to spend more time focusing on patients and increase the number of people seen in A&E. AI Tools for Diagnostics: A core priority is to provide regulatory clarity for AI tools used in radiology and pathology, which are already showing immense promise. Remote Monitoring Systems: The Commission will also address regulatory hurdles for systems that support virtual care of patients in their own homes, alerting staff to early signs of deterioration and helping people live more independently. The causal link between regulatory uncertainty and stalled innovation is clearly understood, and the Commission is positioned as the direct solution to provide the necessary clarity and accelerate the deployment of these technologies across the NHS. Foundational Regulatory and Ethical Challenges: The Commission's Core Mission The Black Box Problem and the Imperative for Explainability The most significant regulatory hurdle the Commission must address is the "black box" nature of many complex AI systems, particularly those that use deep learning algorithms.This opacity means that healthcare professionals cannot fully understand how an AI model arrived at a specific diagnosis or treatment recommendation. This lack of transparency directly conflicts with fundamental medical principles, such as "do no harm" and the ability to obtain truly informed consent from patients, as doctors cannot adequately explain the basis of an AI-assisted decision. Without this critical understanding, trust in the technology among both clinicians and patients erodes, serving as a major barrier to widespread adoption. The MHRA has already recognised this challenge and has dedicated a specific work package, 'Project Glassbox,' to articulate the safety and quality concerns that can arise from poorly interpretable AI. The Commission's new framework is expected to build upon this existing work by providing clear guidance on how manufacturers must demonstrate the interpretability of their products to ensure they are trusted and used appropriately in clinical settings. Algorithmic Bias and the Amplification of Health Inequities Another critical challenge for AI regulation is the risk of perpetuating and even amplifying existing health inequalities through algorithmic bias. This bias often originates from the training data itself, which may not be representative of diverse populations. For example, AI models trained predominantly on data from light-skinned individuals may be significantly less accurate at detecting skin cancer in patients with darker skin tones. When deployed at scale, such biased systems can result in inaccurate diagnoses or substandard care for large, underserved patient groups. The MHRA acknowledges that its existing medical device regulations require products to be safe for their intended use population, but the agency also recognises the need for new guidance to address specific AI-related risks, such as generalisability and bias. The Commission's framework must provide a clear pathway for manufacturers to demonstrate they have actively mitigated these risks, ensuring that AI is inclusive and equitable for all patients. Regulating Continuously Learning (Adaptive) AI The core tension in regulating AI stems from its ability to adapt and learn from new data in real-world settings.Unlike conventional AI models that are "locked" after approval, adaptive AI systems can continually update themselves, potentially becoming more accurate and personalised over time. However, this dynamic nature presents a fundamental challenge to traditional regulatory models, which are predicated on the assumption that a product remains stable after it has been approved. This raises critical questions about how regulators can ensure a system remains safe and effective if it is constantly evolving and how performance updates should be managed. The MHRA has directly addressed this issue with its "AI Airlock" regulatory sandbox, a controlled environment for testing adaptive algorithms before full deployment. The Commission's work is essential to translating this pilot initiative into a scalable, national framework that balances the need for accelerated access to innovative technologies with the critical requirement for continuous post-market surveillance and patient protection. Data Governance, Privacy, and Cybersecurity A robust regulatory framework for AI in healthcare is inextricably linked to stringent data governance, privacy, and cybersecurity standards. AI systems process vast amounts of sensitive patient data, and any framework must ensure that this information is protected and handled with the utmost care. Public trust is paramount, and past controversies, such as the improper sharing of patient data by Google's DeepMind with a UK hospital, have demonstrated how quickly confidence can be eroded. The UK's Data Protection Act 2018 (DPA) provides a foundation for this, but the Commission must ensure that its recommendations for AI regulation align with and reinforce these protections, mandating strong encryption, access controls, and transparent consent policies to safeguard patient information and maintain public confidence. Core Challenges for Regulating AI in Healthcare Challenge Description Relevance to the Commission Transparency and Explainability The "black box" nature of complex AI models makes it difficult to understand how decisions are reached, undermining trust. The Commission's new framework will need to provide guidance on ensuring AI outputs are interpretable and trusted by clinicians and patients. Algorithmic Bias AI models trained on non-representative data can produce biased and inequitable outcomes for certain patient groups. A key focus is to guard against bias and ensure AI is inclusive and equitable, especially for underserved populations. Adaptive AI Regulation The ability of adaptive AI to learn and change post-deployment challenges traditional, static regulatory approval models. The Commission will advise on how to manage post-market surveillance and performance updates for continuously learning systems. Workforce Readiness Lack of AI literacy and skepticism among NHS staff are significant barriers to successful adoption and safe use. While not a direct regulatory issue, the Commission's recommendations for a trustworthy framework will indirectly help build staff confidence and accelerate adoption. Broader Systemic Barriers and The Adoption Landscape Procurement and Funding Hurdles While the Commission's work is focused on regulatory clarity, the analysis reveals that a new rulebook alone will not guarantee widespread AI adoption across the NHS. Significant systemic barriers exist at the local level. Research on the NHS AI Diagnostic Fund, for example, found that the procurement and deployment of AI tools took between six and ten months longer than anticipated. This was largely due to complex and fragmented governance structures, as each of the hundreds of NHS organisations has its own unique IT systems and approval procedures. This variation creates bottlenecks and significantly increases the workload for trusts and vendors alike. Furthermore, existing funding models often favour short-term research and innovation projects over long-term implementation and adoption, creating sustainability challenges that make it difficult for organisations to justify the necessary upfront investment. Workforce Readiness and AI Literacy Another critical barrier is the readiness of the NHS workforce itself. While general attitudes toward AI in healthcare are positive, especially among those with direct experience, many clinicians and staff still harbour concerns about privacy breaches, personal liability, and potential job displacement. This skepticism and the varying levels of AI literacy across the workforce are major implementation barriers. The analysis underscores the need for comprehensive AI education and training, from undergraduate medical curricula to continuing professional development programs. The NHS England AI Team is actively working on initiatives to embed responsible and ethical AI into services and empower staff. The Commission’s work, by providing a trustworthy and transparent regulatory framework, can help to build confidence and mitigate these concerns, but it cannot address the underlying educational and cultural shifts required for successful, large-scale implementation. The MHRA's Pro-Innovation Approach in Context The Commission's work is part of a broader, coordinated MHRA strategy to foster a pro-innovation environment without compromising safety. The MHRA has already launched a regulatory sandbox, the "AI Airlock," to work with manufacturers and clinicians to tackle the challenges of regulating AI as a medical device. The agency has also strengthened the post-market surveillance aspects of its medical device regulations, with new legislation taking effect to increase patient safety through additional obligations on manufacturers for gathering post-market data. This multi pronged approach, combining a high-level advisory commission with practical, on-the-ground pilots, demonstrates a sophisticated understanding of the complex challenges ahead. National Commission into the Regulation of AI in Healthcare Stakeholder Perspectives and The Path Forward A Unified Voice of Support The formation of the Commission has been met with a unified and overwhelmingly positive reaction from key stakeholders across government, industry, and healthcare. Science and Technology Secretary Liz Kendall stated that the Commission will ensure the UK "leads the way" in making these "game-changing technologies" available quickly and safely. Lawrence Tallon, CEO of the MHRA, has emphasised that the goal is to find the "sweet spot" of predictable and proportionate regulation that will bring "clarity and confidence" to the market. The Patient Safety Commissioner, Professor Henrietta Hughes, reinforced the need for careful regulation that is both safe and equitable. Peter Ellingworth, Chief Executive of the Association of British HealthTech Industries (ABHI), welcomed the initiative, highlighting its importance for attracting investment and shaping supportive regulation. This broad-based support signals a high degree of consensus on the importance of the Commission's mission and suggests that its recommendations will have the necessary political and social capital to be successfully implemented. Global Context: The UK's Sector-Specific Approach The UK's approach to AI regulation is a deliberate strategic choice that sets it apart from other major global players. In contrast to the European Union's comprehensive and broad-based AI Act, which classifies most healthcare AI as "high-risk" and imposes a prescriptive set of rules, the UK is pursuing a sector-specific, "pro-innovation" framework. Lawrence Tallon of the MHRA has affirmed that the UK's framework will not be a simple replica of the EU's. This divergence is intended to provide a faster and more flexible pathway to market, thereby attracting global health tech companies to invest and deploy their latest innovations in the UK. By creating a clear, tailored regulatory environment, the UK aims to cement its reputation as a global leader in responsible AI and gain a competitive edge in the global health tech market. Timeline and Expected Outcomes The Commission is expected to launch a formal call for evidence to inform its work in the coming weeks. The culmination of its efforts will be the delivery of a set of recommendations to the MHRA, which will, in turn, inform a new regulatory rulebook on AI in healthcare. This new framework is set to be published in 2026.The MHRA has made a public commitment to act on these recommendations, supporting the NHS's digital transformation and advancing the UK's ambition to become a global hub for health tech investment. Conclusion and Recommendations Synthesis of Findings The UK National Commission on the Regulation of AI in Healthcare is a timely and strategic initiative to bridge the gap between rapid technological advancement and an outdated regulatory framework. The Commission's work is essential for creating a modern rulebook that addresses the unique technical and ethical challenges posed by AI, including the "black box" problem, algorithmic bias, and the regulation of continuously learning systems. While the MHRA has already begun to address these issues through targeted pilots and change programmes, the Commission's role is to formalise these efforts into a coherent, national framework that provides clarity, builds trust, and accelerates the safe adoption of AI across the NHS. However, the report also concludes that the success of this regulatory reform will depend on a parallel effort to address systemic, non-regulatory barriers, such as fragmented IT infrastructure, complex procurement processes, and a lack of AI literacy within the workforce. Forward-Looking Recommendations Based on the exhaustive analysis, the following forward-looking recommendations are proposed to ensure the Commission's work translates into tangible, widespread benefits for the NHS and the UK economy: Prioritise Transparency and Accountability: The new regulatory framework must provide explicit, actionable guidance for manufacturers on how to demonstrate the interpretability and explainability of their AI models. A clear, auditable trail of an AI's decision-making process is essential for building trust among clinicians and patients and for assigning accountability in cases of error. Establish Flexible Pathways for Adaptive AI: The framework should move beyond the traditional, static approval model to create a flexible, risk-based pathway for continuously learning AI. This could involve a combination of rigorous pre-market validation and a robust system for ongoing post-market surveillance that allows for safe, real-time performance updates without requiring constant re-certification. Scale AI Literacy Programs: To overcome skepticism and build competence, policymakers should collaborate with professional bodies to develop and scale AI education and training programs for the NHS workforce. These programs should cover the foundational principles of AI, its ethical implications, and practical guidance on its safe and effective use in clinical practice. Address Systemic Barriers to Adoption: The government must address the underlying operational and logistical challenges within the NHS. This includes standardizing IT systems where possible, streamlining procurement processes, and ensuring that funding models support the long-term implementation and scaling of AI technologies, not just initial research and pilot projects. Continue International Collaboration: The UK should leverage its pro-innovation stance to continue international collaboration with regulatory bodies like the FDA and Health Canada to promote harmonized standards where possible, while maintaining a tailored approach that gives the UK a competitive edge in attracting global health tech investment. By addressing these interconnected challenges, the UK can successfully balance the imperatives of innovation and patient safety, fulfilling its ambition to be a global leader in AI-enabled healthcare and transforming the NHS for the benefit of all. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors Partner Lloyd Price joins the new Silver Buck Advisory Board alongside Senior NHS England staff and Former Secretary of State for Health Silver Buck Advisory Board - Buccaneers Silver Buck is the UK's leading HealthTech PR and Digital Marketing agency. Silver Buck offers a diverse range of services covering PR, Digital Marketing, Social Media and Events for a range of clients looking to create awareness with NHS, Private Healthcare and Government audiences. Advisory board members are some of the most influential health IT, digital health and marketing individuals in the sector. Combined they are the force that is the Silver Buccaneers – pioneers, adventurers and visionaries. The advisory board members are Lloyd Price, Matt Hancock, Umang Patel, Richard Corbridge, Dominic Cushnan, Sam Shah, Jon Hoeksma, Hassan Chaudhury, Rachel Murphy, Trishna Bharadia. https://www.silver-buck.com Silver Buck Silver Buck specialise in crafting tailored strategies and campaigns designed to deliver targeted messages to the appropriate audiences, whether you’re a digital health start-up, B2C health app, NHS trust or a well-established health IT supplier. Our expertise ensures that the right messages reach the right individuals, from NHS CIOs and investors to patients. At Silver Buck, we tell it like it is, we listen to your unique challenges and goals, we hit the ground running and we have proven results. We’re highly flexible and agile in our approach, accommodating to the changing needs of growing companies.. Healthcare demands a different perspective and creative solutions balanced with subtle nuances that often only the healthcare community understand. We aspired to be the leading full-service agency that had walked in your shoes, understood your challenges and had the experience that meant we knew exactly how to solve them. From our foundations in strategic health teach PR, our multi-skilled agency team has grown to include renowned journalists, expert communicators, digital marketing specialists, branding gurus, and creative content creators. However, Silver Buck as an agency has always been synonymous with digital health PR. Silver Buck

Nelson Advisors invited to lead the 'International Investors and European HealthTech' panel at HealthTechX 2025 conference HealthTechX 2025 The HealthTechX 2025 Summit is a one-day event taking place on November 5, 2025, at The Hurlingham Club in London. It's a key gathering for leaders in the health technology sector, including CEOs, founders, investors, and policymakers. Agenda and Key Themes The summit's agenda focuses on how technology is transforming healthcare with a tangible impact. Confirmed session topics include: AI-driven diagnostics: Exploring the latest advancements and applications of artificial intelligence in medical diagnosis. The healthcare workforce gap: Discussing how technology can help address the shortage of healthcare professionals. Medical robotics: Showcasing innovations in robotics and their role in improving patient care and surgical procedures. Specific confirmed sessions for the 2025 event include: Beyond the Hype - AI's Place in Healthcare The Evolution of Telehealth in a Post-COVID World Hospital to Home - Enabling the Continuum of Care From Prescription to Prevention - The Challenge of Lifestyle Change Mental Health and Prevention Hearing from the Investors Speakers and Attendees The event brings together leaders from across the health technology ecosystem. Past and confirmed speakers represent a wide range of organizations, from pharmaceutical and tech giants to innovative startups and investment firms. Attendees can expect to network with individuals from companies such as Merck, IBM, Philips, Takeda, Roche, and AstraZeneca. https://impactx2050.com/healthtechx Nelson Advisors HealthTechX 2025 International Investors and European HealthTech' panel European HealthTech remains undervalued, creating unique openings for overseas investors. This session highlights success stories and the cultural, regulatory and strategic differences to watch. Nelson Advisors Partner Lloyd Price will Chair the panel discussing the European HealthTech Investment Landscape, covering key questions such as: Overall Market and Investment Trends What is the current state of capital flow? Is investment continuing to be concentrated in a few mega-deals, or is there a resurgence in early-stage funding activity? How are macroeconomic factors impacting the market? How are rising interest rates and inflation affecting deal valuations, investor confidence, and the availability of capital? What is the investor sentiment towards European HealthTech compared to other global markets like the US or Asia? Is Europe closing the funding gap, and what are its unique strengths? Which countries or regions in Europe are emerging as HealthTech hubs? Beyond the traditional powerhouses like the UK, Germany, and France, are there new centers of innovation, particularly in Central and Eastern Europe (CEE)? Exits and M&A What is the current state of the exit market? With a subdued IPO market, is M&A the primary exit strategy for HealthTech startups? Who are the most active acquirers? Are exits driven primarily by strategic buyers (e.g., large pharma, medical device companies) or by private equity firms looking to consolidate the market? What deal structures are becoming more common in M&A? Are buyers offering more earn-outs, royalties, or joint ventures to share risk and manage high valuations? Nelson Advisors invited to Chair the panel on the 'European HealthTech Investment Landscape' at HealthTechX 2025 Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading HealthTech M&A advisors in Europe? Executive Summary The landscape of M&A advisory in the European HealthTech sector is highly structured and complex, reflecting the industry's rapid evolution and the strategic imperatives of its participants. A comprehensive analysis reveals that a singular definition of a "leading" advisor is insufficient. Instead, the market is characterised by a bimodal distribution of influence, led by two distinct classes of advisory firms: global financial powerhouses and highly specialised, sector focused boutiques. Global investment banks, often referred to as bulge bracket firms, derive their leadership from unparalleled deal volume, total deal value, and extensive global reach. Their value proposition centers on handling the largest and most complex cross-border transactions for major corporations and institutional investors. In contrast, boutique firms, despite not appearing in top-tier league tables by aggregate metrics, establish their leadership through deep, qualitative specialisation. Their hands-on approach, rooted in a nuanced understanding of specific technologies and market dynamics, makes them the preferred choice for high-growth, niche HealthTech companies. The selection of a "leading" advisor is therefore not a matter of simply identifying the highest-ranked firm. It is a strategic decision that requires aligning the firm's core competencies with the client's specific needs, whether that is global scale for a multi-billion-euro acquisition or highly tailored expertise for a founder-led exit. The following report provides a detailed analysis of this advisory matrix, offering a framework for understanding the key players, their unique contributions, and the strategic rationale behind their selection in the dynamic European HealthTech market. Firm Name Primary Specialisation Key Ranking/Metric Notable European Deals Target Client Profile Nelson Advisors HealthTech/Digital Health (Boutique) Founder-led focus, deep niche expertise, and thought leadership. Various HealthTech and Medtech High-growth HealthTech companies and investors seeking specialized advice. Rothschild & Co Generalist (Bulge Bracket) #1 for European M&A by deal volume/value in 2023. N/A Various HealthTech and Medtech Large corporations, complex transactions, and mid-market deals through its Arrowpoint Advisory partnership. Deloitte Mid-Market (Consulting/Advisory) Leading mid-market M&A advisor in life sciences and healthcare. Advised on Dell/EMC tech deal (globally). Mid-cap companies, private equity, and corporate clients requiring integrated advisory. Houlihan Lokey Generalist (Mid Cap Advisory) #1 for all global M&A transactions by deal count in 2024. Various HealthTech and Medtech Broad range of clients from large corporations to private equity, with a specialized Healthcare Group. Goldman Sachs Generalist (Bulge Bracket) Top M&A financial advisor in Europe by deal value in 2024. Various HealthTech and Medtech Large corporations and institutions involved in high-value transactions. THM Capital Advisory Digital Health/MedTech (Boutique) Specialized in French HealthTech deals. Gleamer's acquisition of Caerus Medical. French-based digital health and medtech entrepreneurs. The Dynamic Landscape of European HealthTech M&A The European HealthTech M&A market is a microcosm of broader economic trends, demonstrating resilience and a strategic shift in capital allocation. Recent data shows a discernible "flight to quality," with a notable increase in deal values for high-growth segments, even as overall transaction counts may be lower. While a report on the healthcare industry showed a significant year-over-year drop in aggregate deal value in Q3 2024, from $13.3 Billion to $2.3 Billion, this apparent contraction does not paint a complete picture of the HealthTech sector. A closer look at M&A fees by industry reveals a critical distinction: fees for the "High Technology" sector increased by a substantial 52% in 2025, while financials and industrials experienced declines. This indicates that capital is not retreating from the market but is instead being reallocated to technology-driven segments. HealthTech, a fusion of these trends, is identified as a top-three industry for weekly funding in Europe, securing €196.5 Million in a single week in September 2025. This demonstrates that the market is not simply shrinking but is undergoing a focused, selective transformation, where tech-enabled assets are commanding increasing value and investor interest. The drivers of M&A activity within the HealthTech sector are varied and strategic, often targeting specific technological and operational capabilities. Artificial intelligence (AI) remains a powerful catalyst, as evidenced by deals like Gleamer's acquisition of two AI firms, Pixyl and Caerus Medical. This transaction was specifically designed to expand Gleamer's AI imaging portfolio to include MRI applications, creating a more comprehensive solution. Similarly, the acquisition of Ro5 by Juvenescence was intended to bolster AI/machine learning drug discovery capabilities.Beyond AI, other key trends include the consolidation of data analytics providers (Cotiviti's acquisition of Edifecs) and the merger of IT and cybersecurity firms to create unified platforms for the healthcare industry (Abacus Group and Medicus IT). These transactions are driven by a need to streamline workflows, reduce redundancies, and enhance efficiency in the complex healthcare ecosystem. Geographically, the European HealthTech M&A market is anchored by several key hubs. The United Kingdom and Ireland stand out as dominant centres, leading all European countries in deal size and volume in Q3 2024. The acquisition of DCC Healthcare by Invest industrial for £1.05 Billion and the strategic purchase of UK-based Momenta by Denmark's Liva Healthcare highlight the concentration of high-value and strategically important deals in these jurisdictions. Other significant regional markets include France, with firms like THM Capital Advisory demonstrating a robust track record in the digital health and medtech space and the DACH region (Germany, Austria, Switzerland), which is served by specialised firms such as Ferber & Co and KP Tech. The presence of these regional experts underscores the fragmented nature of the European market, where local knowledge and networks can be a decisive factor in transaction success. The Two Pillars of Financial M&A Advisory The advisory ecosystem for European HealthTech M&A is defined by a fundamental duality between global financial powerhouses and highly specialised boutique firms. The choice between these two models represents a key strategic decision for any company seeking to navigate a transaction. Bulge Bracket and Global Powerhouses These are the multinational giants of the financial world, characterised by immense resources, global networks, and the ability to execute large-scale, complex transactions. Their leadership is a matter of sheer scale and market dominance. Rothschild & Co: This firm is a formidable leader in the European market, having secured the top ranking for M&A advisory by both deal volume and value in 2023. Rothschild & Co's global advisory team focuses on transactions in healthcare services, pharma, and healthcare IT. The firm's unique model includes a partnership with Arrowpoint Advisory to serve the mid-market in the UK, providing a blend of deep sector specialism and global connectivity that is typically reserved for larger, multinational companies. Goldman Sachs: A clear leader in M&A by value, Goldman Sachs topped the European M&A financial advisor league table in 2024 by advising on $97.5 billion worth of deals. The firm's reputation and extensive resources allow it to execute the largest and most consequential transactions globally. Its position is built on its ability to leverage a vast global platform to advise on high-value, complex deals. Deloitte: As the world's largest professional services firm, Deloitte is a prominent mid-market M&A advisor in life sciences and healthcare. Its value lies in providing comprehensive services that span the entire M&A lifecycle, from strategic planning and due diligence to post-deal integration. The firm's dedicated life sciences and healthcare M&A team is integrated with a global network of advisors, bringing extensive market knowledge and thought leadership to its clients. Mid Cap Advisory Houlihan Lokey: The most active mid-cap advisory firm globally. This firm holds a top position in global M&A, having been ranked as the number one investment bank for all global M&A transactions by deal count in 2024. Houlihan Lokey's value proposition is its combination of scale and sector-specific knowledge. Its dedicated Healthcare Group provides in-depth expertise across a wide range of sub-sectors, including global healthcare technology, medical products, and pharmaceuticals, offering a tailored approach despite its size. Boutique and Specialist Firms These firms operate with a different value proposition, focusing on deep sector knowledge, personalised service, and a hands-on approach. Their leadership is qualitative, measured not by the sheer number or value of deals, but by their influence within a specific niche. Nelson Advisors: This firm is a prime example of a leading boutique. Its influence is not derived from its position in generalist league tables but from its exclusive focus on European HealthTech, digital health, and health IT. The firm’s founders, Lloyd Price and Paul Hemings, bring a unique "founders for founders" approach, having successfully built, scaled, and exited HealthTech businesses themselves. This first hand operational experience provides them with a practical understanding of the challenges and opportunities for founders and investors, a key competitive advantage over larger, less specialised firms. THM Capital Advisory: This firm exemplifies a leading regional specialist. Based in France, it has a strong track record of advising on strategic sales and fundraising for digital health and medtech companies, as demonstrated by its role in the sale of Caerus Medical to Gleamer in 2025. Its expertise is not just in M&A but in navigating the specific dynamics of the French tech ecosystem. Comparative Analysis: Choosing the Right Partner The choice between a bulge bracket and a boutique firm is not a simple matter of selecting the "best" firm. It is a strategic alignment of a firm's capabilities with a client's needs and the nature of the transaction. A high-growth startup seeking a strategic exit, for example, would likely find more value in a boutique with a deep, nuanced understanding of its specific technology and market niche. The flat organisational structure of a boutique allows for direct communication with senior partners and a more flexible, creative approach to deal design. This is in contrast to the hierarchical structure of a bulge bracket firm, where junior staff may have less exposure to senior-level discussions and deals are often managed through more standardized processes. The following table provides a clear comparison of the two advisory models: Dimension Bulge Bracket/Global Powerhouse Boutique/Specialist Firm Target Deal Size Typically focuses on large-cap transactions ($500M to multi-billion). Primarily works with mid-market firms and businesses (sub-$500M). Service Scope Provides a comprehensive range of financial services, including M&A, capital markets, and asset management. Focuses on a limited set of services, most commonly M&A advisory. Team Structure Hierarchical and layered with well-defined roles. Flatter hierarchy, allowing for direct communication with senior staff. Client Relationship Client access is often reserved for senior staff; junior staff manage research and execution. Team members are highly involved in client relationships from the start. Core Value Proposition Global reach, extensive resources, and brand reputation for large, complex deals. Deep sector expertise, highly personalized service, and a hands-on approach. The Critical Role of Legal and Transactional Advisors While financial advisors manage the strategic, financial, and commercial aspects of a transaction, legal advisors are equally critical, overseeing the legal due diligence, regulatory compliance, and contractual documentation. In HealthTech, where intellectual property (IP), data governance (such as GDPR), and complex regulatory frameworks are paramount, a legal advisor's specialised expertise can be as decisive as a financial advisor's network. Latham & Watkins: Ranked as the top legal advisor in Europe by deal value in 2024, the firm demonstrates its capability to handle the most significant and complex transactions. Its practice is praised for its "in-depth" sector knowledge, particularly in medtech and biotech, highlighting its understanding of the innovative technology that defines the HealthTech space. The firm's global platform, with high-quality teams in the UK and Germany, further enhances its ability to advise on cross-border deals. CMS: This firm is the undisputed leader in Europe by deal volume, advising on a total of 265 deals in 2024, far outpacing its peers. The firm's track record in digital health includes advising on the sale of Echo, a UK startup, and the AI firm InstaDeep, underscoring its relevance and activity in the technology-driven segments of the market. White & Case: The firm was ranked as the number one legal advisor for EMEA M&A by deal value in Q1 2024, reflecting its work on 52 significant deals worth a total of $45.4 Billion. Its robust life sciences and healthcare practice regularly advises on M&A and capital markets transactions and has extensive experience handling complex legal issues, including antitrust and patent litigation, which are crucial for HealthTech and medtech companies. Specialist Support: In large, cross-border transactions, the advisory teams often involve a multi-firm approach. For example, in Invest industrial's £1.05 Billion acquisition of DCC Healthcare, the buyer was advised by Arthur Cox LLP and Milbank LLP, while the seller was advised by William Fry LLP. This collaboration between firms with strong regional or specific legal expertise is essential for navigating the intricacies of a deal spanning multiple jurisdictions. Case Studies in European HealthTech M&A The following case studies provide concrete examples of how different advisory models and firms operate in the European HealthTech market. Transaction Name Date Announced Deal Value (Approx.) Key Players Rationale Advisors (Role & Firm) Investindustrial acquires DCC Healthcare April 2025 £1.05 Billion Acquiror: Investindustrial; Target: DCC Healthcare Strategic consolidation, focus on technology-enabled solutions. Legal: Arthur Cox LLP (Buyer), Milbank LLP (Buyer), William Fry LLP (Seller). Gleamer acquires Caerus Medical First half of 2025 N/A Acquiror: Gleamer; Target: Caerus Medical Technology-driven expansion to add MRI capabilities to AI imaging portfolio. Financial: THM Capital Advisory (Seller). Liva Healthcare acquires Momenta February 2025 Undisclosed Acquiror: Liva Healthcare; Target: Momenta Market expansion and consolidation to gain access to UK's NHS contracts. Legal: Acuity Law (Seller). Case Study 1: Large-Scale Healthcare Consolidation The £1.05 billion acquisition of DCC Healthcare by Investindustrial represents a major consolidation play in the European healthcare services market. This transaction, which was announced in April 2025, underscores the trend of private equity firms leveraging their track record to consolidate assets with technology-enabled solutions. The legal advisory team was a multi-jurisdictional effort, with Investindustrial advised by Arthur Cox LLP and Milbank LLP, while DCC was advised by William Fry LLP. The involvement of these leading legal firms, particularly from the UK and Ireland, highlights the cross-border and complex legal due diligence required for such a high-value transaction. The absence of a publicly named financial advisor further suggests that for large-cap deals, the financial advisory role can be internal, or the sheer scale of the transaction may render a formal advisory role less newsworthy compared to a boutique-led deal. Case Study 2: AI-Driven Digital Health Acquisitions In the first half of 2025, the French AI firm Gleamer strategically acquired two companies, Pixyl and Caerus Medical, to enhance its AI imaging portfolio. This case study is particularly insightful as it demonstrates the importance of highly specialised advisory. The strategic sale of Caerus Medical was advised by the boutique firm THM Capital Advisory, which specialises in French digital health and medtech transactions. The rationale behind the deal was purely technological, aimed at adding MRI analysis capabilities to Gleamer's existing X-ray and mammography solutions. This type of transaction, which is not about volume or value but about strategic and technological fit, is a domain where the deep expertise of a niche advisor is highly valued. The seamless integration of a new technology into an existing platform is a delicate process that requires an advisor who understands the nuances of the underlying intellectual property and clinical applications. Case Study 3: Market Expansion Through Acquisition In February 2025, the Danish digital health platform Liva Healthcare acquired Momenta, a UK-based provider of healthy lifestyle programs. The strategic driver for this transaction was to expand Liva's presence in the UK market and, more specifically, to gain access to Momenta's existing contracts with the UK's National Health Service (NHS) and local authorities. The only advisor mentioned in the available public information for this specific deal was Acuity Law, a legal firm that represented the seller, Momenta. This case illustrates that mid-sized, strategically focused acquisitions may not always involve a formal, publicly disclosed financial advisor, or the legal advisory role may be considered the most critical component for a smooth transaction, especially when a key objective is to secure national health contracts. Strategic Recommendations and Future Outlook Based on the analysis of the European HealthTech M&A advisory landscape, the following strategic recommendations and a future outlook are provided for stakeholders. Recommendations for Stakeholders: For High-Growth HealthTech Startups: When planning a fundraising or exit event, it is recommended to engage with a specialised boutique advisor like Nelson Advisors, with their "founders for founders" approach, they can offer a more tailored and empathetic perspective. Their deep understanding of the market niche and hands-on guidance can be more valuable for maximising shareholder value than the broad, standardised services of a larger generalist firm. For Corporate Development Teams and Private Equity: The dual-structure market provides a strategic advantage. It is advisable to use bulge bracket firms for large-scale, transformative "platform" acquisitions that require global reach and extensive resources. Concurrently, it is prudent to engage specialised boutiques for smaller, strategic "bolt-on" acquisitions that require deep sector knowledge and a precise understanding of a specific technology or market niche. This hybrid approach ensures that the right expertise is applied to each component of a portfolio strategy. For all parties: The selection process for an advisor should extend beyond a review of league tables. A thorough due diligence process should be conducted on a firm's specific expertise in a company's sub-sector, including their knowledge of evolving regulatory frameworks (e.g., UK AI regulation), IP law, and the unique challenges and opportunities of the European market. Future Outlook: The European HealthTech M&A market is expected to continue its trajectory of strategic consolidation. As the market undergoes a "flight to quality," M&A will remain the fastest path for companies to acquire critical capabilities, particularly in the rapidly advancing field of AI. A trend of "string-of-pearls" acquisitions is anticipated, where players will seek to build comprehensive, integrated platforms by acquiring early- to mid-stage innovations to fill pipeline gaps and hedge against patent cliffs. The success of specialised boutiques will likely prompt bulge bracket firms to adapt their models. To remain competitive in the high-growth, mid-market space, large firms may develop more specialised, hands-on teams. This could lead to the emergence of new hybrid advisory models that combine the global resources of a bulge bracket with the deep sector knowledge of a boutique, ultimately offering clients a more comprehensive and tailored service. The future of HealthTech M&A in Europe will therefore be defined by a growing demand for nuanced, specialised, and highly strategic advisory services, moving ever further from a one-size-fits-all approach. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

MedTech Malta 2025 The MedTech Malta 2025 event is a three-day summit scheduled to take place from November 12-14, 2025, at the Mediterranean Conference Centre in Valletta, Malta. 🇲🇹 What to Expect at MedTech Malta 2025 The conference is a convergence point for a global audience, including investors, entrepreneurs and healthcare leaders. It aims to foster collaboration and showcase the latest advancements in medical technology. The agenda includes: Panel Discussions & Keynotes: featuring experts from various fields within the MedTech ecosystem. Startup Pitch Competitions: offering a platform for emerging companies to showcase their innovations. Exhibitions: with a focus on cutting-edge technologies. Networking Opportunities: including exclusive forums for CEOs and investors. Cultural Activities & Awards Gala: the event is set against the backdrop of Malta's historic capital, with a cultural tour and the prestigious MedTech World Awards Ceremony. The conference is a CPD-accredited event, providing healthcare professionals with an opportunity for professional development. https://med-tech.world/malta/ European Venture Capital and Private Equity Funds MedTech Malta 2025 will feature over 250 investors and 300 speakers, with 25% of attendees coming from the UK and Europe including: Ken Nelson: A partner at MedTech Advantage Fund with a focus on digital health. Diana Saraceni: Co-Founder and General Partner at Panakes, a venture capital firm that invests in early-stage life sciences companies, primarily in Europe and the U.S. Rachna Dayal: An executive with experience at Philips, Johnson & Johnson, and in venture capital. Greg Madden: A Managing Partner at SV Health Investors, a private investment firm focused on health. The event is designed to facilitate connections and collaboration among various stakeholders in the MedTech ecosystem, with a focus on discussions about capital formation in MedTech, including strategies for early-stage investments and cross-border growth. The MedTech Malta Startup Pitch The MedTech Malta Startup Pitch is a platform for medical technology startups to showcase their innovative products, services, and solutions to a panel of judges and potential investors. This shall provide a unique opportunity for entrepreneurs to gain exposure, receive feedback, and secure funding for their ventures. The event attracts a diverse audience of industry experts, healthcare professionals, investors, and entrepreneurs from around the world. The competition is highly competitive, and the judges evaluate each pitch based on its novelty, feasibility, market potential, and overall impact on healthcare. Top performers receive recognition, networking opportunities, and valuable support to advance their business. Source: https://med-tech.world/malta/pitch/ MedTech Malta 2025 Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Executive Summary This report provides a definitive analysis for venture capital (VC) investment in the value-based care (VBC) healthtech sector. While VBC represents a profound and necessary paradigm shift with a multi-trillion-dollar market opportunity, it is not an environment for unsophisticated capital. The core finding is a qualified "yes": venture capital should strategically back VBC healthtech, but only by targeting specific business models and deploying patient capital with a deep understanding of the unique operational, regulatory, and financial risks. The market is propelled by a macroeconomic imperative to curb escalating costs and is strongly incentivised by top-down regulatory mandates from entities like CMS. However, startups face structural hurdles, including fragmented data ecosystems, notoriously long sales cycles, and resistance from entrenched stakeholders. Case studies of both successful exits (Oak Street Health, Signify Health) and spectacular failures (Cano Health, CareMax) confirm that the nature of the capital is as critical as the business model. The most promising opportunities lie in scalable "enabler" technologies and specialized "single slice" solutions that reduce administrative friction and empower providers to manage risk effectively. The Macroeconomic Imperative for Value-Based Care Market Landscape & Growth Trajectory: A Paradigm Shift The shift to value-based care is not a passing trend but a fundamental reorientation of the U.S. healthcare system, moving from a volume-driven model to one centred on patient outcomes and cost-efficiency. The sheer scale of this transition presents a monumental opportunity. In 2024, the U.S. value-based healthcare service market was valued at an impressive $4.01 to $4.15 trillion. This is not a nascent market; it is a massive, established sector undergoing a profound transformation. Projections indicate a significant and sustained growth trajectory, with a Compound Annual Growth Rate (CAGR) of 7.2% to 7.5% over the next decade, with the market expected to reach up to $8.55 trillion by 2034. This sustained, decade-long growth forecast signals an irreversible and strategic direction for the entire healthcare ecosystem. Analysing the market segments provides a clearer picture of where the momentum is concentrated. The Medicare and Medicare Advantage segments are the most mature, holding the largest revenue share at 48.48% in 2024. This is a critical point, as it shows that the most active and proven market for VBC innovation is tied directly to federal programs. Furthermore, the self-care segment also held a dominant revenue share, accounting for 38.0% to 37.26% of the market, which underscores the increasing emphasis on patient-centric models that empower individuals to actively manage their health. Looking ahead, the Medicaid segment and the institutional care segment are expected to be the fastest-growing categories, highlighting emerging opportunities for new and innovative startups to address underserved populations and settings. Core Principles & Driving Forces of Adoption Value-based care represents a philosophical and financial departure from the traditional fee-for-service (FFS) model, where providers are reimbursed based on the quantity of services delivered, regardless of the outcomes. The core objective of VBC is to align financial incentives with patient well-being, focusing on improving health outcomes, enhancing the patient experience, and reducing costs. This holistic approach is often framed by the Quintuple Aim: improving the patient experience, enhancing population health, reducing per capita costs, supporting the well-being of the healthcare workforce, and advancing health equity. The economic imperative behind this shift is unmistakable; soaring healthcare costs and the increasing burden of chronic diseases have rendered the FFS model fiscally unsustainable, making a transition to more efficient, patient-centered care a necessity rather than an option. Beyond market forces, government initiatives are a primary driver of VBC adoption. The U.S. Centers for Medicare & Medicaid Services (CMS) has set an ambitious and clear goal to have all Medicare beneficiaries in some form of VBC arrangement by 2030. This includes models like Accountable Care Organisations (ACOs) and bundled payment models, which are now being adopted by commercial insurers as well. The CMS GUIDE Model, for example, provides a new payment structure for dementia care that is compatible with existing models and is designed to help older adults with dementia stay healthy at home longer. This top-down mandate from the most influential payer in the U.S. healthcare system serves as a powerful de-risking factor for investors. The market's growth is not merely a function of organic demand; it is a direct result of government policy that provides a guaranteed, long-term demand for enabling solutions. This provides a strong tailwind for patient capital over a typical VC fund lifecycle of 10 or more years, establishing a clear and enduring market direction. The sheer scale of the U.S. VBC market, already over $4 trillion, means that even small, incremental improvements can translate into enormous financial benefits. A study published in Health Affairs provides a powerful illustration of this, showing that VBC models have led to a 5.6% decrease in hospitalizations and a 9% decline in emergency department visits. In such a vast market, a 1% improvement in a key metric could result in billions of dollars in shared savings. This transforms the investment thesis: the focus is not solely on finding "disruptive" technologies but also on identifying "enabler" technologies that can deliver measurable, scalable, and auditable marginal gains. A startup's value proposition is therefore not just about a better product, but about a demonstrably lower cost of care for a defined patient population, making it an indispensable partner in the new healthcare economy. US Value-Based Care Market Projections & Segment Breakdown Metric Details Market Size in 2024 $4.01-$4.15 Trillion Projected Market Size by 2034 $8.55 Trillion Compound Annual Growth Rate (CAGR) 7.2% - 7.5% Forecast Period 2024-2034 Largest Payer Category Medicare and Medicare Advantage (48.48% revenue share in 2024) Fastest-Growing Payer Category Medicaid Largest Service Category Self-Care (37.26% - 38.0% revenue share in 2024) Fastest-Growing Service Category Institutional Care The HealthTech Opportunity: Catalysing Value and Scale Technology as a Foundational Enabler for VBC The successful transition to a value-based care model is intrinsically linked to the adoption of advanced technology. VBC is fundamentally a data-driven model that requires sophisticated tools for managing patient populations and measuring outcomes. To succeed, startups must provide solutions that enable accurate patient attribution, risk stratification, and outcome measurement. The data that informs these decisions must be "accurate, complete, and timely", a requirement that traditional, fragmented health systems often struggle to meet. Artificial intelligence (AI) has emerged as a key technology in this transition. The research indicates that every payer and provider surveyed reports using AI in some capacity. AI is delivering tangible results, with a majority of users reporting improved clinical decision-making, increased operational efficiency, and better patient outcomes. This has not gone unnoticed by investors; there was a 300% increase in investment in biopharma AI since 2023, with mega-deals over $100 million accounting for 71% of the total investment in the sector in 2024. Beyond AI, the rise of telehealth and remote patient monitoring (RPM) is crucial for expanding care beyond the traditional clinical setting. These technologies enable a shift towards proactive and preventive care, allowing providers to manage chronic conditions remotely, reduce hospital risks, and ultimately lower costs. Policy changes, such as those that support the CMS GUIDE Model, are creating new reimbursement pathways for these remote services, solidifying their role as a core component of future VBC models. Proven Business Models & Investment Theses The investment landscape for VBC healthtech is characterized by a variety of models, each with its own approach to generating value and managing risk. Leading venture capital firms have developed distinct investment theses to capture this opportunity. General Catalyst, for instance, champions a "Health Assurance" thesis, aiming to transform healthcare from a "sick care" system into one that is proactive, accessible, and affordable. Their vision is to build an integrated network of companies that co-create the necessary infrastructure for this new ecosystem, rather than operating in silos. Similarly, Andreessen Horowitz (a16z) has an investment thesis focused on "Healthtech Infrastructure," centred on rebuilding the fundamental "utilities and systems-of-record" that underpin all healthcare operations, data exchange, and interoperability. Within these overarching theses, three distinct startup archetypes have emerged as particularly attractive investment targets: "Own the Whole Pie": These companies build comprehensive, end-to-end platforms and take on full financial risk for a defined patient population. The prime example is Oak Street Health, which scaled a national Medicare Advantage platform and was acquired for $10.6 billion, demonstrating that controlling every patient touchpoint can lead to significant venture-scale returns. "Own a Single Slice": This model involves companies that specialize in a high-value, high-cost segment of care. Companies like Strive Health (kidney care) and Thyme Care (oncology) become indispensable to payers by designing every element of their service to effectively manage risk within a specialised domain. "Enable Others to Take Risk": These startups provide the technology and operational infrastructure to empower providers and payers to succeed in VBC arrangements without becoming direct care providers themselves. Aledade and Pearl Health are examples of companies that help independent physicians participate in ACOs by providing analytics, financial alignment, and operational support. Carrum Health provides a similar service for employers, offering a bundled payment platform for specific procedures. The research highlights a critical and often overlooked dynamic in the sector: a "synchronization gap" between payers and providers. While a high percentage of both groups (97-100%) agree on their VBC goals, they are not collaborating at scale. This is not a failure of vision but a significant obstacle in execution, as only about a third of surveyed organisations rate their data integration capabilities as excellent. This fragmentation and lack of coordinated data exchange represent the single greatest investment opportunity. The most valuable VBC startups will be those that act as platforms to bridge this gap, creating a "single source of truth" and coordinated data exchange that aligns all stakeholders. Furthermore, while AI is widely adopted, its full potential remains untapped due to a lack of trust. Concerns about "AI hallucinations," algorithmic transparency, and ethical oversight are widespread and are keeping many leaders cautious. This hesitation is a major bottleneck in a sector built on trust. The market is not just looking for powerful AI, but for trusted AI. This creates an opportunity for VCs to prioritize startups that embed responsible innovation into their core product design, with transparent algorithms, clear human oversight protocols, and robust cybersecurity. This focus on trust and ethics will be a key differentiator and a source of competitive advantage, enabling a startup to build a defensible moat in a rapidly evolving market. VC Theses & Focus Areas in VBC Healthtech Firm Name Investment Thesis Key Focus Areas Notable Investments General Catalyst "Health Assurance" Applied AI, Care Delivery, Ecosystem Integration, Health Equity Livongo, Mindstrong, Color Andreessen Horowitz "Healthtech Infrastructure" AI + Healthcare, Virtual-First, Provider Enablement, Healthcare x Fintech Pearl Health, Fortuna Health Alumni Ventures "Risk Management" Specialized Care (Kidney, Oncology), In-home Care, Patient Engagement Strive Health, Thyme Care, Hopscotch Health Optum Ventures Strategic Healthcare Investment Services, Technology, Care Delivery 75+ portfolio companies Rock Health Digital Health Digital Health Exclusively Omada Health, Collective Health In-Depth Due Diligence: Mitigating Significant Risk Operational & Go-to-Market Hurdles While the VBC market presents immense opportunities, it is also fraught with significant operational and go-to-market challenges that must be thoroughly vetted. The transition to VBC requires substantial upfront investments in technology, data analytics, and care coordination infrastructure, all with uncertain ROI timeframes. This financial uncertainty is compounded by frequent policy changes from entities like CMS, which can disrupt long-term business strategies. The primary reason these startups face a high capital burn is the notoriously long sales cycle. The average enterprise medical software deal takes 12 or more months to close, a "marathon" that can stifle revenue and frustrate teams. A typical deal involves as many as nine decision-makers from various departments, including IT, finance, and clinical staff. This bureaucratic, multi-stakeholder approval process can add months to the timeline, with a new electronic health record (EHR) system for a hospital potentially taking two years to finalise. Beyond the sales process, a significant hurdle is stakeholder resistance. Despite the clear benefits, both providers and patients can be hesitant to adopt new models. Providers, who have operated under the fee-for-service model for decades, may be skeptical of qualitative metrics and fear a loss of revenue during the transition. Patient resistance is also a factor, as many are unaccustomed to the proactive, patient-empowered approach of VBC, and may be more inclined to seek care only when they are sick. Regulatory and Compliance Minefields The healthcare sector is a heavily regulated environment, and a failure to navigate this landscape can be a fatal flaw for a startup. Companies are advised to allocate a significant portion of their budget—20% to 30%—to regulatory affairs. A staggering 70% of healthtech startups report facing regulatory hurdles that delay their time to market, a problem that is exacerbated when compliance issues arise late in the product lifecycle. A critical lesson from the industry is the disproportionate cost of these delays. A study by McKinsey & Co. reveals that a six-month delay to market can result in a 33% loss in profits over five years. This is a far more significant impact than a 50% budget overrun on a product launched on time, which results in only a 4% profit reduction over the same period. This data underscores a powerful, counter-intuitive truth: for healthtech, speed is a more critical factor for long-term profitability than budget adherence. VCs must be prepared to fund a longer, potentially over-budget runway if it means the startup can navigate regulatory approvals and sales cycles more quickly. Compliance requirements are extensive and non-negotiable, including data privacy (HIPAA, GDPR), clinical validation, quality management systems (ISO 13485), and post-market surveillance. The Cautionary Tales of Financial Misalignment The success of a VBC company is not solely dependent on its business model or technology; the nature of its capital is just as critical. The year 2024 provided a stark warning with the Chapter 11 bankruptcies of at least three private equity-backed VBC companies: Cano Health, CareMax, and Miami Beach Medical Group. These companies specialized in value-based primary care for vulnerable populations, including those dually eligible for Medicare and Medicaid. The cause of their collapse was not a flawed VBC model, but a direct result of "extractive financial strategies". These included leveraged buyouts and debt-funded shareholder dividends, which burdened the companies with substantial debt. In one instance, an investor extracted at least $575.7 million from a company through these strategies. This stands in stark opposition to the VBC goals of patient well-being and long-term value creation. The collapse of these companies led to layoffs and clinic closures, demonstrating the fundamental incompatibility of short-term, debt-heavy financial models with the long-term, patient-centric nature of VBC. In contrast, successful, equity-backed VBC companies like Oak Street Health ($10.6B) and Signify Health ($8B) achieved massive exits through acquisition by corporate incumbents like CVS and Amazon. The failures of Theranos and Haven also serve as powerful reminders that a company must have a defensible business model, clinical validation, and a foundation of trust to succeed. This highlights that venture capital, with its patient, equity-based approach, is the right kind of investor for this sector, as it aligns with the long-term, value-creation goals of the business, unlike the short-term, extractive models of some private equity firms. VBC Startup Risk Matrix Risk Category Specific Risk Key Data Points & Impact Financial Upfront Capital & High Burn Rate Requires substantial investment in technology and infrastructure with uncertain ROI. Go-to-Market Notoriously Long Sales Cycle Average enterprise deal takes 12+ months and involves 9+ decision-makers. Regulatory Regulatory Delays & Costs 70% of startups face regulatory hurdles; 6-month delay can cause a 33% profit loss over 5 years. Operational Data Fragmentation Only 33% of providers and 31% of payers have excellent data integration capabilities, creating a bottleneck. Stakeholder Provider & Patient Resistance Clinicians may fear revenue loss; patients may resist proactive care. Lessons from Success & Failure Company Name Outcome Business Model Financial Strategy Key Lesson Oak Street Health $10.6B Acquisition by CVS "Own the Whole Pie" - National Medicare Advantage Platform Equity-backed (VC) Scalable risk management and end-to-end control of care delivery create immense value. Signify Health $8B Acquisition by CVS "Single Slice" - In-home Health Assessments and Bundled Payments Equity-backed (VC) Specialized expertise that enables others to take on risk can lead to lucrative exits. Cano Health Chapter 11 Bankruptcy in 2024 "Own the Whole Pie" - Primary Care for Dual-Eligibles Debt-burdened (Private Equity) Short-term, extractive financial strategies are fundamentally incompatible with VBC's long-term goals. Theranos Bankruptcy & Dissolution Diagnostics Equity-backed (VC) Without clinical validation, transparency, and trust, a business model will unravel regardless of its funding. The Final Verdict: A Strategic Framework for Investment Based on the comprehensive analysis, venture capital should strategically back VBC healthtech startups. However, this is not a sector for unfocused or impatient capital. The investment must be highly strategic, with a deep understanding of the unique market dynamics, a clear eye on the risks, and a commitment to providing patient capital. A Framework for Evaluating VBC HealthTech Startups A successful investment thesis for VBC healthtech requires a robust due diligence framework that moves beyond traditional tech metrics. VCs should evaluate startups based on the following: Team Composition: Does the founding team have a rare blend of deep healthcare industry expertise and scalable technology experience? This combination is essential for understanding clinical workflows and building defensible, integrated solutions. Business Model & Defensibility: Does the startup have a clear, defensible business model? It should fall into one of the proven archetypes—"own a slice," "own the whole pie," or "enable others to take risk"—and its value proposition must be clearly centred on reducing costs and improving outcomes. Data Strategy & Interoperability: A startup's plan to overcome data fragmentation and integrate with existing EHRs and clinical workflows is a core indicator of its potential for success. The value of the company is directly proportional to its ability to create a single, accurate, and integrated data layer that aligns all stakeholders. Go-to-Market Strategy: The startup must have a clear and detailed plan for navigating the 12 or more month sales cycle and the multi-stakeholder approval process. This includes a well-defined channel strategy, whether it's targeting health systems, large employers, or payers. Capital and Financial Model: The financial model must be aligned with the long-term, patient-centric nature of VBC. The runway must be sufficient to survive the extended sales and regulatory cycles, and the plan should not rely on short-term, extractive financial engineering. Strategic Recommendations To succeed in this sector, venture capital funds should adopt a highly selective and proactive investment strategy: Prioritise "Enabler" and "Single Slice" Models: While "owning the whole pie" has yielded large exits, "enabler" and "single slice" models often represent more capital-efficient and defensible businesses. These companies provide the foundational infrastructure that empowers the broader market and addresses high-value pain points. Invest in Data & AI: The greatest market inefficiency is the "synchronization gap" between payers and providers. VCs should back startups that are not just using data and AI but are building a trusted, transparent, and integrated data layer that solves the industry's fragmentation problem. Support Solutions that Reduce Administrative Burden: A key part of the Quintuple Aim is supporting the healthcare workforce. Startups that reduce administrative load for providers, automate reporting, and streamline workflows will have a powerful value proposition that drives adoption and reduces a major pain point. Provide Patient Capital: Understand that this is a long-term play. Be prepared to deploy patient capital with a multi-year horizon, recognizing the extended sales, regulatory, and implementation cycles. This is an environment where the right kind of capital is a competitive advantage. Concluding Outlook The VBC healthtech market is at a critical juncture, moving from a theoretical vision to widespread implementation. However, the true potential of this transition is being bottlenecked by operational fragmentation and a lack of synchronised execution. For venture capitalists, this presents a sector with a clear, macroeconomic tailwind and an abundance of problems ripe for technology-driven solutions. The potential for venture-scale returns, demonstrated by multi-billion-dollar exits like Oak Street Health and Signify Health, is a powerful motivator. But as the cautionary tales of debt-laden failures show, success is contingent not only on a powerful business model but also on a financial strategy that is fundamentally aligned with the long-term, patient-centric goals of value-based care. The opportunity is immense, but it is reserved for those who choose to back companies that are built for enduring health, not short-term financial extraction. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

HealthTech to Watch in 2026: Subconscious Vibro Tactile Stimulation Executive Summary Subconscious vibro-tactile stimulation (VTS) represents a powerful, emerging modality within the HealthTech sector, positioned to transition from a specialised clinical tool to a ubiquitous component of personalised healthcare. Defined as the application of non-invasive mechanical vibration to the skin to modulate neural activity, VTS operates on an implicit level, leveraging the body's natural sensory and proprioceptive systems to effect therapeutic changes in the brain and nervous system. The year 2026 is forecast to be a pivotal period for this technology, driven by a convergence of technological miniaturisation, growing clinical validation and a strong market demand for non-pharmacological, non-invasive therapeutic solutions. The analysis finds that VTS is characterised by a critical duality: it is simultaneously being developed as a rigorously studied, medical-grade therapy for serious neurological conditions and marketed as a direct-to-consumer wellness product for a wide range of applications. In the clinical realm, VTS is demonstrating promising results as a non-invasive, non-pharmacological alternative or adjuvant for movement disorders, including spasmodic dysphonia, cervical dystonia and Parkinson's disease. Its ability to be delivered via wearable devices, from specialised gloves and collars to discreet topical patches, enables the crucial shift from clinic-based care to continuous, at-home therapy. Key market drivers for VTS include the escalating patient preference for drug-free interventions, the perfect alignment of wearable form factors with the rapidly growing telehealth and remote patient monitoring markets, and the indirect technological advancements fueled by the larger, and faster-growing, haptic devices market. Strategic challenges remain, most notably the significant credibility gap between scientifically validated clinical research and the often unsubstantiated claims of consumer wellness products. As the market matures in 2026, success will belong to companies that can navigate this duality, demonstrate favourable unit economics, and build robust partnerships with both academic institutions and healthcare systems. VTS is poised to fundamentally redefine the delivery of care for a variety of conditions, positioning it as a genuinely disruptive force and a key HealthTech to watch. The Neurophysiology of Subconscious Vibro-Tactile Stimulation Deconstructing the Mechanism: From Skin to Cortex The efficacy of vibro-tactile stimulation (VTS) as a therapeutic modality is rooted in its ability to non-invasively manipulate the human nervous system through the body's primary sense of touch. The process begins at the peripheral level with specialized skin mechanoreceptors that are exquisitely sensitive to mechanical vibrations. These receptors include the fast-adapting (FA) type I, or Meissner's corpuscles, which are most sensitive to low-frequency vibrations (around 30 Hz), and the fast-adapting type II, or Pacinian corpuscles, which are highly responsive to high-frequency vibrations (around 250 Hz). As mechanical vibrations are applied to the skin, these receptors transduce the physical energy into electrical signals, which serve as the foundation of the vibro-tactile sensory perception. These afferent signals then travel along a specific neural pathway to the brain's somatosensory cortex, a journey that involves a series of four neural relays. A crucial aspect of this signal transmission is that the mechanical characteristics of the vibratory stimuli, such as amplitude and frequency, are preserved as the signal is decoded at each relay point. Upon reaching the cortical level, VTS is known to modulate activity in key brain regions. For instance, whole-body VTS at 40 Hz has been shown to increase neural activity in the primary somatosensory cortex (SSp) and the primary motor cortex (MOp). This direct modulation of motor and sensory cortices provides the neurophysiological basis for VTS's potential in treating conditions characterised by motor and somatosensory deficits, such as focal dystonias. The influence of VTS extends beyond the somatosensory and motor systems, reaching into deeper brain structures. A growing body of research suggests that VTS can also affect the limbic system, a network of regions including the hippocampus, amygdala, and anterior cingulate cortex that are central to memory, emotion, and cognitive function. This modulation is achieved through pathways involving the vagus nerve, which has well-documented projections to these limbic areas. Studies have demonstrated that VTS, particularly in specific frequency bands, can significantly increase coherence between limbic brain areas, a form of neuronal communication and synchronization. For example, low-frequency VTS delivered to the vagus nerve has been shown to increase coherence in memory-relevant brain regions and reduce inflammatory markers, establishing a clear link between peripheral stimulation and central nervous system effects. The "Subconscious" Effect: Sensory Substitution and Brain Plasticity The term "subconscious" as applied to VTS refers to the brain's capacity to process and integrate tactile information without requiring conscious effort or attention. This implicit processing is a key differentiator from traditional haptic feedback, such as a smartphone vibration, which is designed to be a conscious alert. Subconscious VTS relies on the principle of sensory substitution, where information typically perceived by one sensory modality (e.g., vision, proprioception) is conveyed through another (touch). The brain, through its inherent plasticity, adapts to this new informational stream, incorporating it into its existing neural maps to improve function. The BalanceBelt, a Class 1 Medical wearable device, serves as a prime example of this phenomenon. Designed for patients with severe balance disorders, such as Bilateral Vestibular Loss (BVL), the belt uses an integrated accelerometer and multiple small vibration motors. The system measures the position of the wearer's upper body and provides continuous, non-intrusive haptic feedback. The brain and body begin to process this new information subconsciously within approximately one hour of use, using the tactile signals to recalibrate balance and improve gait. This process allows patients to regain a significant degree of independence by providing the brain with the crucial positional data that their non-functional vestibular organs can no longer supply, illustrating the profound potential of VTS to compensate for neurological deficits. Strategic Implications of VTS Neurophysiology The physiological underpinnings of VTS reveal two critical trends for its future in HealthTech. The first is the technology's dual-modality nature. The analysis indicates that VTS exists in two distinct functional contexts. On one hand, it is a purposeful, conscious interface, as used in research to study tactile speed discrimination or as a display for implicit human-computer interactions. On the other hand, it functions as a non-conscious neuromodulation technique for therapeutic outcomes, such as alleviating muscle spasms or influencing brain states. This functional dichotomy means that VTS products will likely segment into two separate markets: the consumer-facing market for enhancing experiences (e.g., gaming, virtual reality) and the medical-grade market for altering brain and body function. The latter, while requiring more rigorous clinical validation and regulatory oversight, holds the most significant long-term promise for the health sector. The second, and perhaps most impactful, trend is the precision-driven nature of VTS. The effectiveness of VTS is not based on a generalized "buzz" but on the specific parameters of the stimulation. The research points to the importance of stimulation frequency, with gamma frequency (40 Hz) VTS shown to improve motor function and mitigate neurodegeneration in mouse models. Similarly, the Vibrotactile Coordinated Reset (vCR) technique for Parkinson's disease relies on a "specific pattern of vibration" delivered to the fingertips to theoretically disrupt abnormal brain synchrony. This specificity elevates VTS from a simple vibrating device to a sophisticated, targeted therapeutic tool. Future innovation and intellectual property will therefore center not on the simple act of vibration itself, but on the proprietary and clinically proven frequency patterns and algorithms designed to treat a specific medical condition. This move toward precision medicine will be a defining characteristic of VTS development in the coming years. Clinical Validation and Therapeutic Horizons The potential of VTS as a HealthTech is best understood through the lens of its diverse and expanding clinical applications. While much of the research remains in its early stages, several areas show particularly promising results. VTS for Neurological Movement Disorders For individuals with neurological movement disorders, VTS is emerging as a compelling non-invasive, non-pharmacological option. Research by Dr. Jürgen Konczak and his team has focused on VTS as a potential treatment for spasmodic dysphonia and cervical dystonia, both forms of focal dystonia. In a 30-minute application of VTS to the larynx, patients with spasmodic dysphonia experienced measurable improvements in voice quality. For cervical dystonia (CD), a condition characterised by involuntary neck muscle contractions, a proof-of-concept case study demonstrated that VTS can alleviate muscle spasms and reduce pain. An ongoing multi-centre clinical trial aims to further validate these findings, with initial results showing that 66% of participants experienced at least a 10% reduction in perceived neck pain, and 39% reported a reduction of 50% or higher. This pain-relieving effect persisted for up to 20 minutes post-treatment for over half of the participants. Importantly, VTS is being explored as an "adjuvant method" for patients who do not tolerate or wish to supplement their Botulinum toxin (Botox) injections, positioning it as a complementary therapy rather than a direct replacement. Similarly, VTS is being investigated for Parkinson's disease (PD) and essential tremor (ET). A clinical trial is underway to evaluate Vibrotactile Coordinated Reset (vCR) stimulation, delivered via a VT Touch device. This device applies vibratory stimulation to the fingertips in a specific pattern to theoretically disrupt the abnormal brain synchrony associated with PD motor symptoms. The study's primary goal is to determine if vCR can improve motor function and potentially delay the need for increased dopamine medication, offering a flexible, non-invasive alternative to more traditional therapies like Deep Brain Stimulation (DBS). VTS in Rehabilitation and Pain Management Beyond neurological disorders, VTS is finding a role in physical rehabilitation and chronic pain management. For individuals who have experienced a stroke, VTS can be used to reduce spasticity and improve motor function and tactile perception. The mechanism involves stimulating Ia spindle discharge, which can induce reciprocal inhibition of antagonist muscles, thereby reducing muscle tone. Studies on a wearable VTS Glove have shown that daily use can lead to improvements in tactile perception and motor control, with participants reporting being able to wear the device during daily activities, including social events and dining out. The shift from large, clinic-based equipment to a mobile, wearable form factor is critical for increasing accessibility and adherence to at-home therapy. The significant pain reduction observed in the cervical dystonia studies also highlights VTS's potential as a pain management tool. By modulating the nervous system's response to pain, VTS offers a non-opioid, non-pharmacological approach to alleviating discomfort associated with involuntary muscle contractions. Mental Wellness and Quality of Life The applications of VTS extend beyond physical symptoms to address mental health and overall well-being. As a bilateral stimulation technique, VTS engages both hemispheres of the brain, a process that can help calm the amygdala, the brain's alarm system and foster a state of balance and emotional regulation. This makes VTS a promising tool for managing anxiety and post-traumatic stress disorder (PTSD), often incorporated into therapeutic practices like Cognitive Behavioural Therapy (CBT) and mindfulness. VTS also shows significant potential for improving sleep. The HARMONI study on a non-pharmacologic topical patch demonstrated statistically significant improvements in sleep quality and duration. Participants reported a decrease in the time it took to fall asleep, an increase in the number of hours they slept, and a reduction in their use of oral sleep medications after only 14 days of using the patch. These improvements in sleep translated to enhanced quality of life, with reported reductions in daytime fatigue and improvements in mood, concentration, and memory. Strategic Distinctions in the VTS Market An examination of the clinical and commercial landscape reveals a significant distinction in the evidence base and regulatory oversight of VTS applications. Rigorous clinical trials, often funded by institutions like the National Institutes of Health, are investigating VTS for serious neurological conditions like dystonia and Parkinson's disease. These studies are peer-reviewed and follow strict protocols to establish efficacy. In stark contrast, companies marketing VTS products for consumer wellness, such as the topical patches from The Super Patch Company, make broad claims for a wide range of benefits including sleep, athletic performance, and stress reduction. These products are explicitly marketed with a disclaimer that their efficacy has not been reviewed by the Food and Drug Administration (FDA). This regulatory and credibility gap means that while the consumer market will likely see rapid growth due to lower barriers to entry, the clinical market will be more defensible in the long term, with a clear path to medical-grade validation and intellectual property protection around specific therapeutic applications. This difference in market approach also shapes the therapeutic positioning of VTS. The research consistently frames VTS as an "adjuvant" or "alternative" therapy, not a cure. For Parkinson's, it is expected to "delay the need to increase dopamine medication" and act as a flexible option to DBS. This means that VTS products are often best positioned as a supplementary tool within a patient's existing treatment plan, a fact that will shape future go-to-market strategies and commercial partnerships with healthcare providers and systems. The Commercial Ecosystem and Leading Innovators Device Typologies and Market Segmentation The commercialisation of subconscious VTS is being driven by a variety of innovators, each pursuing distinct market strategies. The products can be broadly categorized into two typologies that mirror the clinical-consumer divide. The first category includes specialised therapeutic devices, often developed in collaboration with academic institutions and intended for specific medical conditions. These range from the Vibrotactile Coordinated Reset (vCR) device, which is a glove designed for Parkinson's patients, to the BalanceBelt, a Class 1 Medical Device for individuals with severe balance disorders. A research prototype called VibroSquare also falls into this category, as it is a patch designed to explore implicit interactions and pleasant touch for remote communication. These devices generally aim for clinical clearance and a business-to-business (B2B) model, targeting clinics, hospitals, and medical practitioners. The second category is the consumer wellness market, which is characterised by devices with broader, less specific claims. A key example is the topical "patches" from The Super Patch Company, which utilise a proprietary Vibrotactile Trigger Technology (VTT). These patches, sold under various names for different purposes such as REM for sleep and Victory for athletic performance, rely on direct-to-consumer (DTC) marketing. This approach bypasses the long and expensive regulatory pathway of a medical device, but it also necessitates clear disclaimers regarding the lack of FDA review and prevents the devices from making disease-specific claims. Innovator Profiles: A Case Study in Market Duality Elitac Wearables, with its BalanceBelt, exemplifies the clinically-focused innovator. The product is a Class 1 Medical Device, developed in collaboration with academic and medical institutions. This strategic choice positions the company to serve a specific, underserved population with a validated solution, building trust and a defensible market position based on clinical evidence and regulatory clearance. In contrast, The Super Patch Company represents the high-volume consumer wellness model. Its strategy is based on simplicity and accessibility, the product is a peel-and-stick patch with a wide range of generalised wellness claims. The company's success depends on the power of direct marketing and a low barrier to consumer adoption, not on peer-reviewed, FDA-approved studies. Synergic Medical Technologies is a third type of player, operating in the clinical space but focused on bringing a targeted therapeutic device (VT Touch glove) through the rigorous clinical trial process for a serious neurological condition. The Critical Role of Wearable Technology in VTS Adoption The transition of VTS from a clinic-based therapy to a pervasive HealthTech is intrinsically linked to the rise of wearable technology. Historically, vibratory stimulation studies were limited by large, non-mobile apparatuses. The development of small, low-voltage vibratory motors has enabled the creation of non-invasive, mobile form factors like gloves, belts, and collars that can be worn during daily life, including social events and while performing routine tasks. This shift dramatically increases the accessibility of VTS, enabling continuous, at-home therapy that would be impractical with clinic-based equipment. However, the design of these devices presents significant challenges that directly impact user acceptance and long-term adherence. Research on a wearable VTS glove identified key design considerations, including the ease of donning and doffing for individuals with motor impairments, physical and social comfort, fit, and durability. These factors are paramount, as a device that is cumbersome, uncomfortable, or socially conspicuous is unlikely to be used regularly. This underscores a critical development path for VTS innovators: moving beyond "off-the-shelf" components and developing custom, flexible hardware solutions—such as flexible printed circuit boards (PCBs), that can be seamlessly integrated into clothing or discreetly worn on the body. The Competitive Landscape and Technological Underpinnings The competitive landscape for VTS is defined by two key dynamics. The first is a race for intellectual property and a robust technology stack. The therapeutic efficacy of VTS is rooted in the precise application of stimulation, meaning that simple vibration is insufficient. Innovators are developing proprietary vibrotactile patterns and algorithms to target specific neurological conditions, which will form the core of their intellectual property. This focus on a defensible technology stack, from custom hardware to a library of clinically-proven stimulation patterns, will be a primary determinant of a company's long-term success. The second dynamic is the role of the broader haptic devices market as a powerful enabler for HealthTech. The global haptic devices market, driven by consumer electronics, virtual reality (VR), and gaming, is projected to reach $6.53 billion in 2025 and grow at a CAGR of 16.42% through 2034. This is a faster growth rate and a larger market size in 2025 than the neurostimulation devices market, which is projected at $13.92 Billion with an 11.60% CAGR. The investment and R&D in the haptic market, for products like haptic gloves and wristbands for gaming and AR/VR, will lead to the miniaturisation of components and advancements in hardware that can be readily adapted for VTS HealthTech applications. This provides a clear, indirect growth pathway for VTS that is underwritten by a distinct, high-volume consumer market. Key Market Players and Their Strategic Positioning Company/Researcher Flagship Product Primary Target Market Strategy & Business Model Elitac Wearables BalanceBelt Clinical/Medical (BVL patients) Class 1 Medical Device, B2B collaboration with medical institutions The Super Patch Company Super Patch(e.g., REM, Victory) Consumer/Wellness Direct-to-consumer (DTC) marketing, wellness claims (not FDA-reviewed) Synergic Medical Technologies VT Touch glove Clinical/Medical (Parkinson's patients) Clinical trial-focused, B2B model targeting clinics, with a goal of regulatory approval Jürgen Konczak, Ph.D. VTS for Dystonia Clinical/Medical (Research) Academic research and clinical trials, developing foundational evidence for VTS applications VibroSquare Project VibroSquarePrototype Research/Technology Development Exploring implicit interactions, developing custom flexible hardware for seamless integration Market Dynamics, Investment Trends, and 2026 Forecast Market Sizing and Growth Projections The VTS market in 2026 is an intersection of two large, high-growth sectors: neurostimulation devices and haptic devices. The global neurostimulation devices market is projected to be worth $13.92 Billion in 2025 and grow at a CAGR of 11.60% to reach $37.30 billion by 2034. This market is driven by factors such as the increasing prevalence of neurological disorders, the growing geriatric population, and continuous innovation in device technology. VTS, with its non-invasive approach, stands to capture a significant portion of this market's growth, particularly in areas where traditional therapies are invasive or have side effects, such as for PD and dystonia. In parallel, the global haptic devices market is forecast to grow from $6.53 Billion in 2025 at an even faster CAGR of 16.42%, reaching $25.67 Billion by 2034. While this market is largely driven by consumer electronics and VR/AR, it is a primary engine for the technological advancements, from miniaturisation to improved actuators, that will benefit VTS for healthcare. In 2026, VTS is forecast to benefit from the tailwinds of both markets. The culmination of early-stage clinical trials (e.g., the Parkinson's trial with an estimated completion date in January 2026) and the continuous emergence of new consumer-grade products will accelerate VTS from a niche technology to a recognized HealthTech trend. Growth Drivers and Commercial Barriers The potential for VTS is underscored by several powerful market drivers. First and foremost is the escalating demand for non-invasive, drug-free solutions. VTS offers a powerful alternative to traditional therapies like Botulinum toxin injections for dystonia, which provide only temporary relief, or to Deep Brain Stimulation (DBS) for Parkinson's, which is a major surgical procedure. The appeal of a solution that works with the body's natural systems to reduce reliance on pharmaceuticals is a significant selling point in both clinical and consumer markets. Second, the wearable nature of VTS devices positions them perfectly for integration into the telehealth and remote patient monitoring (RPM) ecosystems, which are experiencing massive growth. A wearable VTS device can enable continuous, at-home therapy and data collection, allowing clinicians to monitor patient progress remotely and adjust treatment plans without the need for in-person visits. This model is highly attractive to both patients and healthcare providers as it reduces friction, improves convenience, and enhances the effectiveness of care for chronic conditions. Despite these drivers, VTS faces significant commercial barriers. The most formidable is the regulatory and reimbursement landscape. The path to FDA clearance for a medical device is a long and expensive process, a critical hurdle for any company aiming for clinical market penetration. Even with clearance, the lack of established reimbursement models or CPT codes can limit adoption, regardless of efficacy. Furthermore, the prevalence of consumer-grade products with unsubstantiated claims could lead to widespread skepticism and a placebo effect, which a clinical trial noted in a sham control group. This dynamic requires a concerted effort by the industry to produce large-scale, robust clinical data to prove efficacy and build credibility. The Investment Landscape and Strategic Trajectory The HealthTech investment climate has shifted, with a move away from the over enthusiasm and high valuations of 2021. Investors are now prioritising companies that can demonstrate favourable unit economics and a clear, near-term return on investment. This scrutiny places a premium on VTS companies that have either a defensible B2B model with a clear pathway to regulatory approval and reimbursement or a high-volume, low-cost consumer model with a robust, data-driven marketing strategy. The market trajectory suggests that companies that can position their VTS solution as a way for health systems to alleviate pressures like staff burnout and improve patient outcomes outside of the clinic will find a receptive sales channel. Health systems are increasingly seeking solutions that are cost-effective and allow for the transition to value-based care, making VTS wearables a compelling partnership opportunity. VTS Market Context & Forecast 2025-2026 Market Size in 2024 Size in 2025 Projected CAGR (2025-2034) Global Neurostimulation Devices $12.45B $13.92B 11.60% Global Haptic Devices $5.61B $6.53B 16.42% U.S. Telehealth (Remote Patient Monitoring segment) - Over $13B by 2026 - Conclusion & Strategic Recommendations The analysis confirms that subconscious vibro-tactile stimulation is more than a fleeting trend; it is a multifaceted HealthTech modality driven by a potent synergy of clinical evidence, technological innovation, and patient-centric demand. The year 2026 is poised to be a critical inflection point where the first generation of clinical and consumer products solidify their respective market positions and begin to demonstrate long-term viability. The central challenge for the sector will be to bridge the credibility gap between rigorous medical research and mass-market consumer claims, a process that requires transparent communication and robust, repeatable data. Strategic Recommendations For Investors: Conduct thorough due diligence to distinguish between companies with a defensible, evidence-based approach and those making broad, unsubstantiated wellness claims. Favor companies with strong intellectual property surrounding specific, clinically proven stimulation patterns and algorithms, as this is where the long-term value will reside. The most promising opportunities exist at the intersection of the clinical and consumer markets, where a company can leverage a high-volume, low-cost consumer model to fund the expensive clinical trials required for a medical-grade, reimbursable device. For R&D Leaders: Move beyond simple vibration and focus on developing and validating frequency-specific and patterned stimulation protocols for targeted therapeutic effects. Prioritize user-centered design to ensure devices are physically and socially comfortable, durable, and easy to use. The ultimate success of at-home VTS depends on long-term patient adherence, which is directly tied to a superior user experience. Invest in flexible hardware solutions that can be seamlessly integrated into clothing or other discreet form factors. For Industry Players: Build strategic partnerships with academic institutions and research hospitals to generate the high-quality clinical data necessary for regulatory approval and market credibility. Explore collaborations with telehealth and remote patient monitoring platforms to integrate VTS devices into broader care ecosystems, which will provide a clear value proposition to healthcare systems looking to reduce costs and alleviate staff pressures. In conclusion, the paradigm of healthcare delivery is shifting from episodic, clinic-bound interventions to continuous, personalised, and at-home care. VTS, in its wearable, non-invasive form, is perfectly positioned to serve as a key driver of this transformation. As the technology matures and clinical evidence mounts, subconscious vibro-tactile stimulation is expected to emerge as a cornerstone of the next generation of non-pharmacological therapies, fundamentally altering how a wide range of neurological, motor, and mental health conditions are managed. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Separating Signal from Noise in the AI HealthTech Market Executive Summary: Distinguishing Signal from Noise The current healthcare innovation economy presents a compelling and complex paradox for investors. The broader US healthcare venture capital fundraising landscape has experienced a significant decline, with the total for the first half of 2025 at just $3 Billion, a steep drop from the previous year. This puts the sector on track for its worst fundraising year in over a decade. This market contraction is largely attributed to economic and political uncertainty, coupled with a general struggle with federal spending cuts in the healthcare industry. However, this market-wide downturn is not uniform. Juxtaposed against this backdrop is a remarkable surge in AI-driven health-tech deals. Trailing twelve-month health-tech AI deal activity has grown nearly two-fold since 2022, accounting for almost one-third of all healthcare investment in the first half of 2025. Furthermore, a recent analysis showed that for the first time, AI-enabled startups secured the majority of U.S. digital health investment, hauling in $4 billion of the $6.4 billion raised in the first half of the year. This included nine of the eleven "mega deals" (deals over $100 million) during the period. This divergence in funding trends suggests a strategic shift in capital toward solutions that can demonstrably address the healthcare industry's most enduring pain points. The "AI Factor" is not merely a buzzword; it represents a calculated movement of capital. The divergence signals a flight to quality within a troubled market, where investors are selectively and aggressively backing AI ventures that present a clear, tangible value proposition. The underlying logic is that while traditional health-tech may be subject to macro-economic pressures, AI, when applied correctly, offers a path to outsized returns by improving efficiency and reducing costs at a scale previously impossible. This reframes the evaluation problem from "is AI a buzzword?" to "which AI applications are positioned to succeed financially?" Part I: The New Healthcare Economy – A Market Undergoing AI-Driven Transformation Market Size, Growth Trajectory, and Core Drivers The AI in healthcare market is characterized by robust, resilient growth, driven by acute and systemic needs. The global market, valued at approximately $14.92 billion in 2024, is projected to reach $110.61 billion by 2030, advancing at a compound annual growth rate (CAGR) of 38.6%. Other projections are even more optimistic, with a 2024 valuation of $29.01 billion and a forecasted market size of $504.17 billion by 2032, exhibiting a CAGR of 44.0%. This astonishing growth is a direct result of critical market needs that AI is uniquely positioned to address. The primary market driver is the rising need to address workforce challenges and cost pressures. As the global population of elderly individuals aged 65 or older is expected to double by 2050, healthcare systems worldwide face significant strain and resource challenges. AI provides a scalable, cost-effective solution for elderly care by offering proactive and personalised interventions. Furthermore, a significant portion of healthcare professionals' time is consumed by administrative tasks, leading to widespread burnout. For instance, physicians spend approximately two to three hours on documentation for every hour of patient care, with some emergency physicians working eight to twelve hours after their clinical shifts to complete charts. AI-powered documentation and workflow automation have the potential to reduce this administrative burden by handling about 50% of routine tasks, saving the average physician fifteen to twenty hours per week. A second critical driver is the rising demand for early disease detection and personalized care. AI's ability to analyze vast medical datasets enables the early detection of diseases years before the onset of symptoms. A generative AI tool named Delphi-2M, for example, can predict the risk of over 1,000 diseases up to 20 years ahead by analysing anonymised patient data and identifying patterns of medical events and timelines. This predictive capability is a key driver for growth in the diagnostics and early detection segment of the market.The market's high growth forecast is not based on speculative technology but on AI's proven ability to solve acute, systemic problems. The causal relationship is clear: as healthcare systems face mounting demographic, staffing, and financial pressures, they are compelled to adopt innovative solutions. The surge in AI investment is a direct response to these pressures, making it a defensive and high-growth investment. The adoption of AI is becoming a necessary infrastructure for ensuring the future viability of healthcare delivery. Widespread Adoption and Demonstrable ROI The market has moved beyond theoretical potential to widespread, practical application. A 2025 NVIDIA report reveals that AI adoption is already a reality, with 63% of healthcare and life sciences professionals actively using AI and another 31% piloting or assessing initiatives. This widespread adoption, compared to a 50% average in other industries, indicates a clear shift from theoretical potential to practical application. The financial benefits of AI in healthcare are no longer speculative. The report highlights that 81% of respondents saw increased revenue, and 73% reported reduced operational costs. This tangible return on investment (ROI) is a critical factor driving increased AI budgets, with 78% of organisations planning to increase their AI spending in 2025. The clear, bottom-line benefits of AI explain the paradox of investment trends. While the overall market contracts, investors are willing to pay a premium for startups that can deliver on this promise. The causal relationship is that a startup's value proposition is not about the technology itself, but about the quantifiable ROI it has already achieved or has a credible path to achieving. The investment criteria for AI-driven health-tech should therefore focus on the measurable impact on revenue or cost rather than on a technology's innovative nature alone. AI in Healthcare: Market Size and Growth Forecasts (2024-2032) Source 2024 Market Size (USD) 2025 Market Size (USD) 2030/2032 Forecast (USD) CAGR MarketsandMarkets $14.92 billion $21.66 billion $110.61 billion (2030) 38.6% (2025-2030) Fortune Business Insights $29.01 billion $39.25 billion $504.17 billion (2032) 44.0% (2025-2032) Part II: The Investment Framework - A Blueprint for Due Diligence Beyond the Pitch Deck: The Multidimensional Team The founding team is a non-negotiable criterion for investors in the health-tech space, who place immense value on its composition. A crucial element is a multidisciplinary blend of business acumen, technical expertise, and, most importantly, clinical domain knowledge. A team that includes doctors, nurses, or other medical professionals demonstrates a deep understanding of the end-user's workflow and the real-world problem being solved. This specialised expertise is essential to "de-risk" the investment by ensuring the product addresses genuine pain points. A team of purely technical founders might develop a brilliant algorithm that solves a theoretical problem but fails to integrate into complex clinical workflows, leading to user frustration and failure. The team's composition is a leading indicator of whether the company understands the systemic challenges of healthcare. An investor should look for teams that can attract and retain this specialised talent, as it is a strong predictor of long-term success. The Technology and Intellectual Property (IP) Core A critical task for investors is to discern whether a startup's "AI Factor" is a core, proprietary innovation or a commodity integration of pre-existing frameworks. A defensible technology is often tied to intellectual property, such as patents for medical devices or trade secrets for proprietary AI algorithms. It is a common mistake for founders to assume their algorithms or training data are automatically protected. A robust IP strategy is not optional; it is essential for long-term viability. This strategy must include strong confidentiality controls, copyright registration for the underlying code, and watertight IP assignment agreements with all employees and contractors from the very beginning. Without a clear and defensible IP strategy, a startup risks losing its competitive edge to a larger, better-funded competitor. In a field where data is increasingly viewed as a valuable asset, the value of a startup isn't just in its model but in the unique, clean, and proprietary dataset it was trained on. Investors should perform thorough legal due diligence to ensure IP is properly protected and that the company has not used unlicensed datasets for training its models. The Unflinching Gaze: Clinical Validation and Regulatory Hurdles Clinical validation represents a critical red flag in due diligence. A JAMA Health Forum study found that many AI-enabled medical devices (AIMDs) enter the market with "limited or no clinical evaluation" because the FDA's 510(k) clearance process does not require prospective human testing. This lack of real-world evidence is directly linked to early performance failures and recalls. In fact, approximately 43% of recalls for AIMDs occurred within one year of FDA authorisation. This suggests that investor pressure for rapid launches may lead to the use of less rigorous regulatory pathways, which in turn results in products with a high risk of early failure and loss of clinician trust. The FDA's traditional paradigm for device regulation was not designed for adaptive AI and machine learning technologies. While the agency is working on new guidance and frameworks, a startup's regulatory strategy must be transparent and comprehensive. Investors should be cautious of companies that have not undergone rigorous clinical studies or are relying solely on the 510(k) pathway without providing additional clinical evidence. The legal and financial implications of a recall or malpractice claim are significant and can undermine a company's reputation and financial viability. The "black box" nature of many AI models poses a significant liability risk, as an incorrect output could lead to patient harm. Legal liability is ambiguous in such cases, and a viable startup must have a clear strategy for mitigating this risk, including transparency and a clear disclaimer of medical advice. An investor must demand tangible proof of clinical efficacy, beyond a simple regulatory stamp. Monetisation and the Business Model A validated product is of little use without a clear and viable path to revenue. Investors must scrutinise the monetisation strategy, particularly the path to reimbursement by insurers or government payers.The sales process in healthcare is notoriously long, often taking 12 to 24 months from first contact to a signed contract, and the lack of established Current Procedural Terminology (CPT) codes for many AI services remains a significant hurdle. The problem isn't just building a great product; it's getting paid for it. The healthcare sector is slow to change, and a startup's success is tied not just to its technology but to its ability to navigate a complex and often antiquated reimbursement system. This explains why some companies with great technology may fail—they have not solved the business model problem. Proven business models for health-tech AI include Software as a Service (SaaS), Tech-enabled Services, and Direct-to-Consumer (DTC). A successful startup must have a clear and credible plan for generating revenue within this challenging landscape. AI Healthcare Startups: A Due Diligence Checklist for Investors Evaluation Area Key Questions to Ask Red Flags Team Does the founding team have a mix of business, technical, and clinical expertise? Have they demonstrated an ability to attract top-tier talent? Absence of clinical co-founders or advisors; a team composed solely of technologists. Technology & IP Is the AI model proprietary, or does it leverage off-the-shelf frameworks without significant innovation? Is there a clear IP protection strategy (patents, trade secrets, copyright)? Lack of a clear IP roadmap or reliance on an IP strategy that hasn't been legally vetted. Regulatory & Clinical Validation Has the company conducted rigorous clinical studies or real-world evidence programs? What is the FDA or other regulatory pathway, and how is it being managed? Relying solely on the FDA 510(k) pathway without additional clinical data; a history of early recalls or performance failures. Business Model Does the company have a clear and viable path to monetization and reimbursement? What is the sales cycle, and is there a strategy to navigate it? Vague or unproven reimbursement strategies; over-reliance on a single revenue stream. Data & Ethics Is the training data high-quality, representative, and de-identified? What measures are in place to address privacy, security, and algorithmic bias? Using non-representative datasets; lack of robust data anonymization or encryption protocols. The Lessons from the Field – Case Studies in Success and Failure What Works: The Blueprint of Success Successful AI health-tech companies are not selling a "gadget"; they are building infrastructure. Tempus AI is a prime example of a company that understood the value of data aggregation and interoperability. Founded on the mission to personalise cancer care, Tempus has amassed the "world's largest library of clinical and molecular data". Their success stems from a multi-revenue stream model that includes clinical testing services, partnerships with pharmaceutical companies for R&D, and subscription services for healthcare providers. Tempus's value lies not in a single algorithm, but in the comprehensive ecosystem it has built around its data. Similarly, Aidoc's aiOS exemplifies the importance of an integrated platform approach over a single "point solution." While point solutions are effective at addressing a single problem, they often fail to scale because they create fragmented data and disconnected workflows within a hospital system. Aidoc's aiOS orchestrates intelligent workflows, integrating seamlessly into existing hospital systems to reduce fragmentation and improve efficiency. The common thread in these successes is that they are not just selling an algorithm; they are selling a solution that fits into an ecosystem. Tempus's "data library" and Aidoc's "operating system" are genuine infrastructure plays, not mere add-ons. The companies that solve the underlying data and workflow problems are more likely to achieve scalable adoption and generate multiple, defensible revenue streams. Learning from Failure: Identifying the Red Flags The downfall of IBM Watson Health serves as a cautionary tale of "overpromising and underdelivering". Despite a $4 billion investment, Watson struggled with integrating messy, unstructured patient data and relied heavily on a curated dataset from Memorial Sloan Kettering Cancer Center, limiting its ability to learn from real-world cases. It also failed to gain widespread clinical adoption due to a lack of physician trust and high implementation costs. The company's attempt to "encompass the entirety of cancer treatment" was too ambitious for its immature technology, and its inability to perform reliably in complex, real-world settings led to its eventual sale. Olive AI's collapse demonstrates the perils of a "lack of focus" and a "one-size-fits-all" approach. The company's aggressive growth strategy led to a poor customer experience, as its platform failed to meet the specific needs of diverse clients, from large hospital networks to small clinics. Olive AI was unable to secure additional funding and was forced to sell off its assets, proving that rapid growth is meaningless if customers are dissatisfied and the product does not deliver on its promises. The core lesson from these failures is the danger of prioritizing hype over substance. Both companies focused on grand visions rather than solving specific, well-defined problems within the existing healthcare infrastructure. The causal chain is clear: inflated expectations lead to underperformance in complex real-world settings, which results in a loss of customer and physician trust and an inability to secure further funding. This is why investors must scrutinise a startup for red flags such as a lack of clear product-market fit, reliance on curated rather than real-world data, and a failure to demonstrate clear ROI. Comparative Case Study: Success vs. Failure Factors Company Vision/Focus Technology Approach Data Strategy Business Model Outcome Tempus AI Success: Focused on a niche (oncology, then expanded) and solved a core problem of data fragmentation to enable precision medicine. Success: Built a proprietary data "library" and platform (not a point solution) to enable analytics and multiple use cases. Success:Aggregates vast amounts of real-world clinical and molecular data from partnerships. Success: Multiple revenue streams from clinical testing, pharma partnerships, and provider subscriptions. High Valuation & Growth: Valued at over $8 billion, demonstrating strong investor confidence. Aidoc Success: Solves the specific problem of workflow inefficiency and fragmentation with a unified operating system. Success: Developed an integrated platform, aiOS, that orchestrates multiple AI solutions and connects data/teams. Success: Focuses on leveraging high-quality, real-time imaging data to provide immediate clinical value. Success: Provides a scalable SaaS platform that integrates into existing systems with minimal effort. Proven Impact: Demonstrated success with top hospitals, with metrics like a 22% reduction in turnaround time. IBM Watson Health Failure: Attempted to solve the "entirety of cancer treatment," a vision that was too broad for its technology. Failure: Relied on a proprietary "black box" system that was difficult to integrate and adapt to real-world workflows. Failure: Over-reliance on curated data from a single partner (MSKCC) and struggled with unstructured, real-world data. Failure: High implementation costs, low ROI, and an inability to secure clinical adoption led to the sale of its assets. Financial Failure: Sold off assets after significant investment due to profitability issues and strategic missteps. Olive AI Failure: Lacked a clear focus, adopting a "one-size-fits-all" approach that failed to serve diverse client needs. Failure:Overpromised on automation capabilities, with customers finding the software still required significant human intervention. Failure: Failed to tailor its offerings, leading to poor data integration and a lack of practical benefits for clients. Failure: Focused on acquiring new customers over retaining existing ones, leading to bad customer experience and financial fallout. Financial Failure: Was unable to secure additional funding and was forced to sell off its assets. Critical Barriers and Unaddressed Risks Even with a strong team and a viable business model, significant barriers and risks can impede the success of an AI health-tech startup. Data Privacy, Security, and Governance: AI's reliance on massive amounts of sensitive health data creates significant privacy risks. While regulations like HIPAA exist, the threat of cyberattacks and data misuse is persistent. A key vulnerability is that machine learning algorithms can re-identify de-identified data, particularly with large, complex datasets, a problem current de-identification methods cannot fully address. This requires new regulations and a proactive approach to due diligence. A startup must have robust data anonymisation, encryption and Business Associate Agreements (BAAs) in place with all vendors to protect Protected Health Information (PHI) and build investor confidence. Algorithmic Bias: This presents a looming ethical and financial risk. AI models trained on non-representative or historically biased datasets can perpetuate healthcare disparities, leading to unequal treatment and a loss of patient trust A widely cited study, for example, found that a common pulse oximeter algorithm was less accurate for patients with darker skin, leading to a median one-hour delay in oxygen delivery for these patients. Investors must probe a startup's data collection and continuous monitoring strategies to ensure they are actively working to mitigate bias and promote equitable outcomes. The Human Factor: Trust and Adoption: The slow uptake of AI in healthcare is often a human problem, not a technical one. Concerns around the predictability of AI, the loss of a human touch, and legal liability are key barriers to adoption. The "black box" nature of many AI models makes it difficult for healthcare professionals to understand and trust the recommendations. A successful startup must not only build a reliable product but also foster trust and demonstrate how the technology augments, rather than replaces, human expertise. The most successful AI applications will be those that empower, not sideline, clinicians. These risks are interconnected and represent the final layer of diligence that separates a mature startup from an immature one. Poor data governance and unresolved issues of privacy and bias can compromise trust among clinicians and patients, which in turn leads to slow adoption and financial failure. An investor must recognize that these are not abstract ethical concerns but tangible financial risks that can directly impact a company's valuation and long-term viability. Conclusion: A Forward-Looking Investment Thesis Artificial intelligence is not a passing fad in healthcare but a powerful force transforming the industry from within. While the overall venture capital market may be facing headwinds, the AI health-tech sector is flourishing because it is uniquely equipped to address the systemic pressures of cost, workforce shortages, and the demand for personalised care. For the discerning investor, the opportunity lies in moving beyond the buzzword and conducting rigorous, multidimensional due diligence. Based on the analysis, a forward-looking investment thesis should be guided by several key principles: Focus on Infrastructure, Not Gadgets: Prioritize companies that are building integrated platforms and solving core workflow challenges, such as Aidoc's aiOS, rather than those offering disconnected "point solutions." The future of healthcare AI is in the operating system that connects fragmented data and systems. Demand Tangible Validation: Insist on rigorous clinical studies and real-world evidence of efficacy. A simple FDA clearance is a starting point, not the conclusion of diligence. A startup must be able to prove its technology provides a measurable benefit to patients and providers. Scrutinise the Team and Data: The quality and completeness of the team, especially its clinical and multidisciplinary expertise, are the most reliable predictors of success. This is inextricably linked to the company's data strategy. A startup with a mature approach to data quality, privacy, and bias mitigation is a de-risked investment. The future of AI in healthcare belongs to ventures that can seamlessly blend technological prowess with a deep, nuanced understanding of clinical realities, regulatory complexities, and the human element. For the discerning investor, this is where the signal truly emerges from the noise. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk